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CHAPTER 1:

Introduction and Background
Human CNS & Neurovascular Units
The human central nervous system (CNS) contains a rich vascular network
consisting of billions of glia and neurons that have innumerable associations with
blood vessels (1). Most notably, blood vessels function to deliver vital nutrients and
oxygen to satisfy the metabolic demands of the brain, but also function to
communicate with brain parenchymal cells. This fundamental communication has
been correlated to proper CNS development and homeostasis (2). Blood vessels in
the brain have unique structural and functional features known as the blood brain
barrier (BBB). Endothelial cells lay the foundation for the BBB, which regulates the
movement of molecules in and out of the brain parenchyma (3). The endothelial
cells of the BBB are joined by adherens and tight junctions and lack the common
fenestrations found in peripheral organ vascular beds (4). This barrier allows for the
selective transport of oxygen and carbon dioxide via simple diffusion while nutrient
transfer, i.e. glucose usually occurs via active transport (5).
The cellular interface between vascular and nervous systems, or the
neurovascular unit (NVU), is crucial for the development and homeostasis of the
BBB (6). The NVU is a multi-cellular complex made up of vascular, neural and glial
cell types (Figure 1) (7). Ablumenally, the endothelial cells are surrounded by a
basement membrane rich in extracellular matrix (ECM) proteins. Like other organs,
smooth muscle cells and pericytes provide structural support for blood vessels in
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the brain. Adjacent to the vascular/pericyte complex are the astrocytes and
neurons.

While astrocytes have many functions, they are best known for their

support of the BBB integrity via their astrocytic endfeet (8). They are also important
for regulating oxygen and nutrient provisions for the neural tissue.

Neuronal

interactions with astrocytes are essential to modulate rates of cerebral blood flow as
required for proper nervous tissue homeostasis (6). The astrocytic endfeet interact
with many ECM ligands present in the cerebral blood vessel’s basement membrane
through various cell-surface adhesion molecules, such as integrins (9).
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Figure 1. The Neurovascular Unit
(A) At the vascular lumen, endothelial cells are connected by tight junctions
that form the BBB. Astrocytic endfeet play roles in tight junction maintenance and
structural support. Neurons and NSCs also closley juxtapose the cerebral blood
vasculature. This figure was adapted from McCarty et al. 2005 (4).

(B) A 20,000x

transmission electron micrograph illustrates the juxtaposition of an astrocyte (Aoutline in red) to a cerebral blood vessel (V).
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Integrins
Integrins are transmembrane glycoproteins that are comprised of a single
(α) and beta (β) subunit that heterodimerize in the endoplasmic reticulum and golgi
prior to arrival at the cell surface (Figure 2b) (10). These subunits form a noncovalent complex and contain small transmembrane and cytoplasmic domains and
a large extracellular domain (11). In humans, there are 18 α subunits and 8 β
subunits that lead to 24 heterodimeric combinations (Figure 2a) (10).

The α

subunits are generally larger than their β subunit binding partners (11). β subunits
contain disulfide-rich bonds, an extracellular domain consisting of four repeats of
forty amino acid cysteine-rich motifs and a relatively small cytoplasmic domain (11).
Integrins are metazoan-restricted and are considered to be major adhesion
receptors to ECM proteins although some are involved in cell-cell interactions (12).
These two fundamental roles allow for cell attachment to the ECM as well as the
ability to harbor those ECM signals intracellularly (13).

Integrins regulate many

cellular processes including, but not limited to, migration, proliferation, invasion and
angiogenesis during normal embryogenesis and development (11) into adulthood
(14). They have been implicated in a variety of diseases including many different
types of cancer (15).
Integrins become activated in two different ways: inside-out or outside-in
signaling (16). One commonality between the two signaling mechanisms is the
necessity of the transmembrane domain to facilitate a signal across the cell
membrane (17).

Inside-out signaling involves an extracellular ligand binding its

cognate receptor, which causes a structural change in the talin protein, leading to
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binding at the NPxY motif of the β subunit’s cytoplasmic tail (18). Furthermore,
Kindlin-3 is essential for talin’s role in integrin activation (19). The head region of
talin, like many other integrin-recruited proteins, contains a FERM (Protein 4.1,
Ezrin, Radixin, Moesin) domain that binds to and can activate integrins. Talin also
links the integrin to the actin cytoskeleton upon interacting with alpha-actinin and
vinculin (20). The intracellular signaling events that occur upon cytoplasmic
interactions are very complex and some are cell-type specific (17). In the inactive
state, integrin α and β subunits associate tightly with one another, but upon talin’s
interaction with the β subunit’s cytoplasmic tail, a conformation change causes the
alpha and beta extracellular domains to separate (10),

allowing for increased

affinity for ECM ligands (13). Conversely, outside-in signaling involves signals from
the ECM to the inside of the cell. Upon binding to ECM ligands, integrins cluster in
the membrane and signal inside of the cell (10). Both ways of signaling allow for
cell anchorage to the ECM via cytoskeletal associations upon integrin activation.
Integrin ECM ligand specificity can be divided into four major groups: [1]
laminin-binding, [2] collagen-binding, [3] leukocyte and [4] arginine-glycineaspartate (RGD)-recognizing integrins (21). Laminin-binding integrins include α3β1,
α6β1, α6β4 and α7β1, although these integrins do bind other ECM proteins (22).
The α subunits are thought to be the major player in ligand-specificity (23).
Although these three alpha subunits have significant sequence similarities to one
another, their specificity is distinct based upon the β subunits they dimerize with at
the cell surface. For instance, although α6β1 and α6β4 share the same alpha
subunit, they tend to bind different laminins in the ECM (23). Based upon this
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information, laminin-binding heterodimers retain higher affinities for different
laminins present in the ECM (24).
Collagen-binding integrins include α subunits 1, 2, 10, 11 that all interact
with β1 to form heterodimers (25). Similar to most alpha subunits, their heads are
created from a 7-bladed β-propeller domain that interacts with the αI-domain in
specific locales (10).

Structurally, these specific integrins are similar, but their

affinity for certain subtypes of collagen is evident (26).

For instance, α1β1

preferentially binds Type IV collagen, whereas α2β1 has increased affinity for
fibrillar collagens (27) and play different roles in cellular processes, such as cell
proliferation and matrix remodeling, respectively (28).
Leukocyte-expressed integrins include α4β7, αEβ7 and αL, αM, αX and
αD, all of which bind β2 (29). They play roles in naïve T-cell circulation, activation
and eventual T cell homing and localization (30).

In areas of infection or

inflammation, leukocytes extravasate from the circulation heavily mediated by
integrin expression. Integrins aid in immobilizing the leukocytes upon the infected
site’s endothelium and function to direct their migration across the endothelium’s
basement membrane to aid in the anti-inflammatory response (31). These integrins
are expressed in other circulating immune cells and they also mediate cell-cell
adhesion via counter receptors, such as V-CAM 1 and I-CAM 1.
Lastly, arginine-glycine-aspartate (RGD)-binding integrins include the αv
subfamily of integrins (αvβ1, β3, β5, β6, β8), α5β1, α8β1 and αIIbβ3 (29). The RGD
tripeptide motif is present in a variety of ECM ligands including vitronectin,
fibronectin and latent-associated peptide (LAP)-TGFβ. The RGD motif interacts
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with the α and β subunits where the arginine has affinity for the β-propeller
component of the α subunit and the aspartate interacts with the von-Willebrand
factor A-domain of the β subunit (32). LAP-TGFβs have the RGD tripeptide motif in
the LAP portion of the inactive cytokine. Upon αvβ6 integrin binding of the motif,
the inactive cytokine is activated allosterically (17). Similarly, αvβ8 integrin has
been shown to bind the same motif and recruit metalloproteinases to aid in the
cleaving of the pro-peptide into an active cytokine (33).

	
  

7	
  

Figure 2. Mammalian Integrin Family
(A) The mouse and human integrin family trees are comprised of 18α and 8β
genes that can form 24 heterodimeric combinations. This figure was adapted from
Hynes et al. 2002 (29). (B) Integrins are comprised of a single α and single β
subunit that are involved in extracellular adhesion and intracellular signaling. (C)
Our laboratory focuses upon the αv subfamily of integrins, which binds with 5
different β subunits: β1, β3, β5, β6 and β8. This dissertation examines the roles of
αvβ8 in glioma-induced angiogenesis.
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αv Integrins
The primary group of RGD-binding integrins is the αv subfamily.

As

mentioned above, αv binds five different β subunits, β1, β3, β5, β6, β8 (Figure 2c).
αv integrins are broadly expressed throughout the body on a variety of different cell
types.

Some include epithelial, vascular and CNS cell types that indicates αv

integrins’ involvement in a multitude of cellular processes (34). To determine the
necessity of the αv subfamily of integrins during various processes, ranging from
development to birth, a mouse harboring a αv integrin null gene was created. It was
evident that there were developmental issues concerning the loss of αv integrin, as
neonates were not being born in the normal Mendelian ratios (1:2:1). Therefore,
embryos were analyzed starting at embryonic day 8.5 (E8.5) until birth. It was
shown that αv integrins are not required for normal development up to E9.5 as
littermates wildtype, heterozygous or homozygous-null were morphologically and
developmentally normal (35). Between E9.5 and E11.5, distinct defects start to
arise in the αv-null embryos where they began to appear delayed in growth and
development and affected mice continue to deteriorate and are eventual absorbed,
mainly due to placental layering abnormalities. These affected mice continue to
deteriorate and are eventually absorbed.

The mice that pass this stage of

development are born viable although they begin to develop bi-lateral intracerebral
hemorrhage at E12.5, which gets progressively more severe towards birth.
Intracerebral hemorrhage is first evident in the ganglionic eminence in the
telencephalon and continues into the diencephalon and slowly into the cortex of the
forebrain and midbrain.
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hemorrhage, (Figure 3a) and also have cleft palates (35). The intracerebral
hemorrhage, together with the inability of the neonates to feed, leads to their
inevitable death (35). Conditional knockout strategies have demostrated that the
lack of expression on glia, and not the vascular endothelium, in the brain is the
reason for the intracerebral hemorrhage (36). While these data are very intriguing,
it is necessary to determine which αvβ heterodimer is responsible for these
developmental and neonatal deficiencies.

αv-associated β subunits
The β1 integrin subunit heterodimerizes with 10 different α subunits resulting
in the largest integrin subfamily. Utilizing homologous recombination in embryonic
stem cells, β1-null mice were created to further understand the necessities of this
subunit in various developmental stages.

Analysis of embryonic development

reveals that β1 integrin is not required during the blastocyst stage to E3.5. Although
the blastocyst has the ability to implant into the uterine wall, they die afterwards at
E6.5 (37).

β3-null mice were generated and have been documented as being

viable and fertile (38). In some instances, hemorrhage has been reported in β3
mutants, although, it is believed that the absence of αIIb integrin expression is the
reason for this phenotype (39).

β5-null mice exhibit no obvious developmental

pathologies and have the ability to reproduce normally (40). The β6 subunit is
expressed mainly on epithelia including the lung, skin and kidney (41). β6-nulls
develop and reproduce normally, but have been shown to develop emphysema-like
pathologies in the lungs and skin due to defective activation of latent TGFβs (42).
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Lastly, β8 subunit’s primary site of expression is within the CNS (43). Similar to αvnull mice, β8-null mice develop two different subclasses of deficiencies. Embryonic
lethality due to defective vascular development in the yolk sac and placenta has
been documented in the majority of cases. The remaining minority consists of mice
being born with severe intracerebral hemorrhage (Figure 3b,d), evident from the
abnormally dispersed capillaries with hyperplastic endothelial cells (Figure 3f), and
in some cases, a cleft palate (44). Based on the evaluation of the αv-binding β
subunits, the specific heterodimer, αvβ8, is responsible for the intracerebral
hemorrhage observed in the complete αv knockout animals.

Moreover, αvβ8

interacts between perivascular neural cells and ECM ligands of the cerebral blood
vessel basement membrane (45), giving further credence towards evidence that the
heterodimer is responsible for those vascular pathologies.
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Figure 3. αv and β8 Integrin Subunit Knockout Models
(A) αv-/- and (B) β8-/- neonates develop acute intracerebral hemorrhage at
E11.5 (arrows).

(C) Wild type animals develop normally while intracerebral

hemorrhage becomes progressively more severe towards birth in both knockout
mouse models (β8-/- P1 neonate displayed Fig. 3D).

(F) β8-/- brain coronal

sections reveal hemorrhage, endothelial hyperplasia and tortuous vasculature
(arrows) compared to normal (E) wild type cerebral vasculature (arrows) (36).
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αvβ8 Integrin
Moyle and colleagues first discovered the β8 subunit in 1991 in rabbit and
human tissues, where they showed it to have a unique polypeptide structure
compared to other known β subunits. Human β8 is comprised of a large
extracellular domain and small hydrophobic transmembrane domain followed by a
hydrophilic cytoplasmic domain.

Northern blot analysis shows β8 mRNA is

expressed primarily in the brain with lower levels being detected in the ovary,
uterus, kidney and placenta as well as several transformed cell lines (46). Initial
studies of ECM ligand adhesion showed vitronectin as one ECM ligand that αvβ8
integrin has the ability to bind (47), although more recent studies would suggest
otherwise.

Using an affinity-based immunoprecipitation assay, Venstrom and

Reichardt determined that the β8 subunit can also bind laminin 1, collagen type IV
and fibronectin (48). Furthermore, αvβ8 integrin has been shown to bind the RGD
domain of LAP-TGFβ1 and 3 leading to bioactivation of the pro-peptide (49).
Aside from multiple ligand specificity, the β8 cytoplasmic domain amino acid
sequence is unique.

All other β subunit cytoplasmic tails share homology

containing one or two NPxY motifs that are binding sites for various
phosphotyrosine-binding (PTB) domains. The α binding subunit cytoplasmic tails
are quite different except for the GFFKR region that is the association site between
the α and β subunits (10). Tyrosine phosphorylation in the NPxY motif of the β
subunit cytoplasmic domain leads to interaction with intracellular proteins at the
plasma membrane. A common PTB domain-containing protein that is recruited to
the cytoplasmic tail of the β subunit is a protein known as talin. As previously
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described, talin binds an NPxY motif present in most β subunit cytoplasmic tails,
although β8’s cytoplasmic tail lacks this common binding site (20). Yeast two hybrid
technology identified β8’s cytoplasmic domain as a binding partner for Band 4.1B.
Other isoforms of Band 4.1s were also shown to have some interaction, although
common cytoskeletal scaffolding proteins did not (50).

Band 4.1 proteins have

three specific functional domains, a FERM domain, a central spectrin/actin-binding
domain and a C-terminal domain (CTD) (51).

The CTD interacts with β8’s

cytoplasmic tail rather than the FERM domain that interacts with other β subunits
(50).
Within the CNS, αvβ8 integrin has been documented to be present in
neurons in the brain and spinal cord as well as glia, such as astrocytes (48).
Furthermore, conditional deletion using Cre-Lox technology revealed that the
integrin is not required on vascular cells (Tie2-Cre) within the CNS. Ablation of
αvβ8 integrin in neurons did not lead to the intracerebral vascular pathologies
evident in the complete αv and β8 knockout animals, but conditional deletion in
neuroepithelia (i.e. GFAP+ astrocytes), recapitulated the intracerebral hemorrhage
(52). These data suggest that it is the interaction between the astrocyte and the
cerebral blood vasculature that is responsible for the phenotype upon αvβ8 integrin
loss (49).

Moreover, αvβ8 integrin mediates contact and communication events

between perivascular glial cells and ECM components of the vascular basement
membrane (45).

Upon integrin ablation, several vascular pathologies arise

including the aforementioned intracerebral hemorrhage as well as vascular
thrombosis, edema and endothelial hyperproliferation. When β8 integrin knockouts
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were first generated, they were created on a C57BL/6J and 129/Sv background that
did not allow for the knockouts to survive post-natally (44). Upon backcrossing onto
an ICR/CD1 mixed genetic background, 50% of β8-/- neonates survive to adulthood
and some live as long as 5 months post-natally, although they develop severe
neurological defects.

Furthermore, αvβ8 integrin regulates neurogenesis and

neurovascular homeostasis in the adult mouse brain (14). The most striking aspect
of the complete αv and β8 knockout mouse models are the vascular abnormalities,
which strongly resemble those vascular pathologies characterized in human highgrade glioma. Since it is the distinct expression of αvβ8 integrin on the glial cell that
controls the vascular pathologies in the knockout models, and given the fact that
glial cells are putative cells of origin for gliomas, it becomes necessary to
investigate the involvement of αvβ8 integrin in human high-grade gliomas.

Glioma
Glioma is an extremely deadly cancer affecting nearly 30,000 patients in the
United States annually (53). These tumors represent the most common type of
primary brain cancer where the most advanced cases epitomize some of the most
fatal forms of cancer (54). Regardless of recent progress in cancer diagnosis and
treatment, glioblastoma multiforme (GBM), the highest grade of glioma, becomes
highly invasive with an innate ability to elude modern surgical, radio- and
chemotherapeutic interventions (55). Therefore, determining the basic cellular and
molecular events contributing to glioma-induced angiogenesis and progression may
lead us to new therapeutic strategies to remedy or inhibit this disease.
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The World Health Organization (WHO) has developed a scoring pattern for
different subtypes of glioma ranging from Grade I to IV. There are several tumor
types that arise from various CNS cell types, including astrocytes, oligodendrocytes
and ependymal cells (Figure 4a) (56).

A large majority of research has been

focused upon tumors of the neuroepithelia that arise from these cell types.

In

general, Grade I tumors are considered to be clinically benign because of their low
proliferative potential and their ability to be managed with surgical resection with
minimal tumor recurrence. Grade II tumors comprise infiltrative cells which often
recur post-surgical resection, even though they also retain a low proliferative
potential. Grade III, anaplastic astrocytomas, for example, are often a result of
grade II tumor’s increase in malignancy. This grade of tumor is best known for their
regions of nuclear atypia and enhanced mitotic activity. Lastly, grade IV tumors, or
GBM, are highly malignant and mitotically active, often characterized for their
pseudopalisading necrotic and angiogenic pathologies (56). Upon diagnosis with
GBM, the median survival rate remains a dismal 9-12 months, even with the
previously described clinical interventions, while patients diagnosed with grade II or
grade III gliomas have been documented as surviving on average 10-15 years and
2-3 years, respectively (57).
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Putative Cell of Origin in Glioma
The cell of origin for gliomas still remains a controversial subject as tumors
have been documented as having astrocytic, oligodendroglial, ependymal or mixed
components (58). Most of the cells found in the brain are fully differentiated and
non-proliferative, therefore the cell of origin is thought to be one that maintains its
ability to proliferate and/or differentiate (59).

More recently, it has been

hypothesized that GBMs may arise and/or recur from neural stem cells (NSCs) that
undergo genetic mutations in tumor suppressor genes and oncogenes (57).

Three

routes have been established for the propagation of gliomas: [1] the neural stem cell
(NSC); [2] the glial progenitor (maintains the ability to differentiate into astrocytes
and oligodendrocytes) and [3] the fully differentiate glial cell (Figure 4b) (60). NSCs
are located in two specific locations in the brain; the subventricular zone (SVZ) of
the lateral ventricle and the subgranular zone of the dentate gyrus of the
hippocampus (57). These cells retain self-renewal capacities and have the ability to
differentiate into the cell types found in the brain, thus the attraction of targeting
them with therapies.

Due to the high degree of cell proliferation, the germinal

regions in the SVZ have often been thought to be the source of gliomas as opposed
to other niches harboring more fully differentiated, non-proliferative cell types (61).
Non-neoplastic cells that transform and produce astrocytic- and oligodendrocyticbased gliomas or mixed oligoastroctyomas are likely direct descendants of a
common NSC. For many years, the astrocyte had been thought to be the source of
most gliomas, although recent evidence involving the cancer stem cell (CSC) has
become a hot topic (62). There are two CSC hypotheses in the field that are of
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ongoing debate: 1) the stochastic model identifying every cell having the same
ability to acquire somatic mutations and produce tumor lesions and 2) the
hierarchical model whereby a distinct subset of cells (<5%) having the ability to
produce tumor (63). The latter of the two is currently the more accepted model.

	
  

18	
  

Figure 4: Glioblastoma Multiforme Tumor Formation
(A) CNS cell types likely originate from a common neural stem cell (NSC).
The NSC differentiates into either neural or glial progenitors.

The neural

progenitors give rise to neurons while the glial progenitors give rise to astrocytes,
oligodendrocytes, and ependymal cells. (B) Tumors of the CNS are thought to arise
from a variety of different sources (dashed arrows). A brain cancer-propagating cell
can give rise to fully differentiated cancer progeny or a progenitor cell type, while
both can create CNS tumors, such as GBM.

(C) Genetic pathways leading to

primary and secondary GBMs are different based on their specific alterations.
Primary and secondary GBMs have common loss of chromosome 10q while p53
mutations are more common in secondary GBMs. (*) Represents specific genetic
alterations that are significantly different between the two paths to GBM. This figure
was adapted from Hadjipanayis et al. 2010 (A, B) and Ohgaki et al. 2007 (C) (54,
60).
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Figure 4
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Molecular Pathologies in Glioma
There are two different routes for GBM to arise, primary and secondary.
About 90% of GBMs arise de novo (1°) without any prior evidence of malignancy
while the other 10% (2°) arise from lower grade II or III gliomas (Figure 4c) (54).
Gliomagenesis has been a widely studied area to make it possible for more
effective interventions to eradicate the disease upon patient diagnosis. As with
many tumor types, there’s a rich body of literature focused upon molecular and
cellular alterations in glioma. Many gene expression profiles and chromosomes are
commonly altered, often correlating with histological grade and clinical prognosis
(53). It is common to observe overexpression of a variety of growth factors (i.e.
PDGF, FGF2) and their cognate receptors (53, 64).

Overexpression of growth

factors and their receptors commonly leads to induced amplification of downstream
proteins, such as Ras and Akt, involved in cell proliferation and survival (65). Also,
the p53 protein is often mutated, affecting cell cycle control (66). Furthermore, in
grade III anaplastic astrocytomas, additional disruptions of cell cycle control
machinery are evident with INK4a/Arf deletion leading to loss of inhibition of cyclindependent kinase 4 (CDK4) and MDM2, respectively. This loss of inhibition causes
an inhibition of retinoblastoma (Rb) and p53, respectively (53). p53 mutations along
with mutations in neurofibromatosis 1 (Nf1) has also led to tumors of various grades
(67).

The cancer genome atlas (TCGA) has identified somatic mutations or

deletions in Nf1 in nearly 25% of a 206-glioma patient sample size, therefore
suggesting a role for the molecule as a potent tumor suppressor (67). Moreover, in
grade IV gliomas, there are additional alterations that supplement the already
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serious changes evident in lower grade gliomas. These include common loss of
chromosomal region 10q22-25, which harbors many tumor suppressor genes,
particularly PTEN (phosphatase and tensin) (68). PTEN acts as the key component
in the negative feedback loop of Akt where it inhibits the functional activation of Akt
via dephosphorylation of PIP3 to PIP2 (69). Additionally, epidermal growth factor
receptor (EGFR) is amplified or hyperactivated via mutation in 30-50% of GBMs
leading to signal transduction activation of intracellular protein cascades, such as
the MAPK, JNK and Akt pathways, involved in pro-survival and pro-proliferative
cellular processes (70).

Together, a majority of the changes in cell signaling

become important players in the development of a high grade gliomas (68).
Conversely, recent data from TCGA has identified mutations of isocitrate
dehydrogenase 1 and 2 (IDH1/2) in about 12% of secondary GBMs where it has
increased the overall rate of survival of patients as compared to those patients
harboring wild type IDH1/2 (71).

This non-biased approach has implicated

mutations in these molecules as having pro-survival effects rather than the
alternative, providing nearly two- to three-fold higher median survival rates for
patients diagnosed with anaplastic astrocytoma or GBM (72). Collectively, TCGA
analysis has provided further understanding of the molecular alterations that occur
in glioma, which in turn, may lead to the development of effective therapeutics to
potentially prolong survival of diagnosed patients.
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Clinical treatment of Glioma
Currently, standard first line treatment for GBM is surgical resection and
acute radiotherapy (RT) alongside simultaneous temozolomide (TMZ) treatment,
followed by adjuvant treatment of patients with the same chemotherapeutic (73).
This concomitant approach allows for modest improvement in overall median
survival rates from 12 months to 14.6 months compared to patients treated with
radiotherapy alone (74). Indeed, there are subsets of patients that survive past 2
years post-diagnosis, but with RT and TMZ dual therapies, the percentage of these
patients increase from 10% to 26% (74). Newly diagnosed GBM patients exhibiting
promoter methylation of the MGMT gene have been documented to respond best to
the RT/TMZ combined therapeutic regimen, increasing overall survival to 23 months
(75).

Although these numbers are encouraging, further efforts are ongoing to

acutely treat patients based more so on their molecular signatures in their tumors,
although the main obstacle of treatment has and continues to be the blood brain
barrier (76).

More recently, advancement in therapies has commenced in the

development of anti-angiogenic agents. Bevacizumab, an anti-VEGF-A humanized
monoclonal antibody, has been recently approved by the FDA for patients with a
recurring GBM (77).

While the data supporting this decision was quite

encouraging, the use in newly diagnosed patients is frowned upon as it may cause
issues in areas of surgical wounds.

Other anti-VEGF therapies have been

established based on the knowledge of VEGF receptors. Previously, soluble decoy
receptors for VEGF have shown poor in vivo pharmacokinetics, including low affinity
for the growth factor and minimal half-life, therefore, further research was performed
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to overcome those shortcomings. This research led to the development of a more
potent VEGF blocker, VEGF-Trap, which maintained high affinity for the growth
factor while increasing in vivo pharmacokinetics of previously documented soluble
decoy molecules (78).
Furthermore, other anti-vascular agents have been examined for glioma,
although limited response has been documented and many of the drugs are still in
pre-clinical development.

Other than the aforementioned soluble receptors and

bevacizumab, angiogenesis is also being targeted intracellularly where drugs such
as cediranib, vatalanib, and sunitinib target cytoplasmic receptor tyrosine kinase
activity of the VEGF receptors 1-3 and cKIT. In addition, sorafenib, pazopanib and
vandetanib target the same intracellular tyrosine kinase activity of EGFR and
PDGFRα, respectively (79).

Possible anti-VEGF therapies concomitant with

radiotherapy may be the best route to treat patients based upon their genetic
prognostic indicators, especially those recurrent patients.

Further research is

ongoing targeting these highly angiogenic tumors to prolong overall patient survival
with minimal side effects while also addressing the invasive phenotype of highgrade glioma cells that are often the source of tumor recurrence post-VEGF
therapy.
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Figure 5: Mouse Models of Astrocytoma/GBM
Table: A partial list of mouse models that mimic human astrocytoma/GBM
that are developed from known glioma-associated genetic alterations (66, 80, 81).
Gross pathologies of a coronal section of a human GBM (bottom-left, red arrows)
are recapitulated by intracranial implantation of a GFP-labeled human glioma cell
line into athymic mice (bottom-right, black arrows). Pathologies include intratumoral
hemorrhage, thrombosis and edema (arrows).
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Animal models of Glioma
Animal models of cancer have long been the flagships for understanding
tumor biology in a dynamic setting.

The most common of these is the use of

immunocompromised (nude) mouse models, including orthotopic and nonorthotopic xenografts (Figure 5 Table). Orthotopic models involve the implantation
of a cell type into its normal microenvironment within the same species while
xenograft models allow for the use of different species, such as the injection of a
human cell line into a mouse.

Collectively, these models have been the most

beneficial in recapitulating the human disease in vivo as oppose to transgenic
models (Figure 5) (82).
Genetically engineered mice (GEM) have also been used to study gliomas.
A model with germline mutations of neurofibromatosis 1 and p53 (Nf1-/-;p53-/-)
leads to the development of astrocytomas, ranging from low to high grade (Figure 5
Table) (66).

Additionally, an RCAS/tva model allows for the cell type-specific

induction of tumors utilizing an avian retroviral delivery system to initiate loss of
tumor suppressors and/or overexpression of oncogenes that have been associated
with glioma (Figure 5 Table) (81). Additional inducible models are available where
specific cell types can be targeted for conditional deletion of tumor suppressors or
activation of potent oncogenes.

The GFAP-CreERT2 or Nestin-CreERT2 have

been used to conditionally delete a gene of interest, such as p53, Nf1 and PTEN,
where they are flanked with loxP sites to allow for cre recombinase activity to
conditionally inactivate them upon exposure to tamoxifen (83, 84). Furthermore, an
additional model was created utilizing the S100β promoter to transgenically express
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a

transforming

homologue

of

EGFR,

which

resulted

in

low-grade

oligodendrogliomas (85). Collectively, multiple models have been established to
evaluate specific genes in the development of glioma.

Glioma and Integrins
Integrins are known to play critical roles in normal and neoplastic cell
adhesion and motility.

The interaction between the ECM, which is a major

component of the CNS microenvironment, is essential for integrin function, and
integrins promote the invasion and migration of glioma cells throughout the brain
parenchyma (86).

Furthermore, normal brain tissue versus GBM tissue was

analyzed for integrin expression using immunohistochemistry.

GBM tissue

displayed increased overall integrin expression as compared to normal tissue (87).
Moreover, the necessity of integrins in GBM has become evident based on
preclinical studies, as therapeutics have been developed to act as antagonists, i.e.
cilengtide (88). Cilengtide has been used in the clinic to target those patients with
RGD-overexpressing integrin profiles, such as αvβ3 and αvβ5 integrins. These
integrins contribute to adhesion and migration of tumor cells (89). Abnormal cellECM interactions can often be a source of gliomagenesis, especially in its early
stages. This interaction allows for anchorage to perivascular regions in the brain
promoting tumorigenesis (90). Similar to many primary tumor populations, gliomas
start out as a relatively avascular lesion, which require the co-option of the preexisting vascular network to progress as well as migrate to other non-hypoxic
regions of the brain (91). Additional to tumor cells adhering ECM components of
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the vascular basement membrane, they are also known to direct their migration
along white-matter tracts (57).

These two methods of migration are often the

reason for GBM recurrence post-therapy and poor prognosis upon initial diagnosis
(92).
Integrins have been implicated in the onset and progression of gliomas for
many years (93).

The fibronectin receptor, α5β1, is considered to be a pro-

angiogenic integrin that is overexpressed in both tumor-associated endothelial cells
and gliomas, alike (94, 95). Laminin is most concentrated around the vascular
basement membrane. Laminin-binding integrins, α3β1 and α6β1, are commonly
expressed in glioma cell lines and are often mediators of migration as well (96).
Limited research has been focused upon the αv subfamily of integrins in relation to
gliomagenesis, although data surrounding the role of αvβ3 and αvβ5 integrins has
been obtained. Both integrins are expressed in endothelial cells and glioma cells,
but have been shown to be concentrated along the tumor periphery, suggesting
their roles in invasion (97). Moreover, glioma growth and invasion was reduced
upon exposure to a small molecule peptide against αvβ3 integrin (98). Conversely,
when β3-/- astrocytes were immortalized and transformed ex vivo and implanted
back into the brain, significantly larger tumors resulted, suggesting the role of αvβ3
integrin as a possible tumor suppressor (99). Perhaps, αvβ3 integrin expression at
the periphery plays a fundamentally different role in overall tumor biology as
opposed to ubiquitous expression throughout the tumor. Nevertheless, these data
suggest the role of αv integrins in glioma biology; however limited research has
unraveled the roles for other αvβ heterodimers.

	
  

28	
  

Aside from the obvious invasive nature of gliomas, microvascular
proliferation and other angiogenic pathologies mark high-grade gliomas (100).
During gliomagenesis, especially at early stages, tumor cells often co-opt the
intratumoral vasculature, disrupting the cohesive nature of the BBB, leading to leaky
or hemorrhagic vessels that allow increased nutrient and oxygen delivery (101). As
the tumors progress, they become hypoxic and nutrient-dependent, thus relying
upon angiogenesis to remedy their situation.

Angiogenesis is defined as the

physiological process from which new blood vessels are created from pre-existing
ones (102). Although the role of αvβ8 integrin has yet to be established in glioma,
there are multiple reason for studying its probable involvement. First, αvβ8 integrin
is expressed in NSCs and astrocytes within the brain, both of which have been
documented as putative sources of gliomas (14, 50, 58). Second, αvβ8 integrin has
also been documented in several glioma cell lines and primary tissues, both at the
mRNA and protein levels (103). Third, upon αv and β8 integrin ablation in the CNS,
vascular pathologies ensue that mimic high-grade glioma vascular pathologies (35,
52). Fourth, GBM stem cells, much like non-neoplastic stem cells, reside in areas
of vascular niches, both of which express αvβ8 integrin (14, 104). These results
suggests that the integrin may play an unknown role in gliomagenesis as it plays
significant roles in regulating neurovascular homeostasis within the adult brain (14).
Collectively, the data in regard to integrin biology and gliomagenesis is clear
although limited focus has been placed upon αvβ8 integrin. Understanding the
functional role of αvβ8 integrin during glioma-induced angiogenesis may prove
pivotal in the discovery of a more specific therapeutically targeted approach to the
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disease alongside increased prevention and early diagnosis. As current treatments
for high-grade gliomas are few and inefficient, it is essential to determine novel
therapeutic target genes, which could help in prolonging or eradicating the
progression of glioma.

In this dissertation, we will analyze the roles that αvβ8

integrin plays in the onset and progression of GBM in regard to tumor growth and
angiogenesis. Moreover, we will substantiate the known role of αvβ8 integrin in
regard to homeostatic control of the BBB, by focusing on its potential role in the
glioma setting.
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Figure 6: Working Model
Expression of αvβ8 integrin on perivascular astrocytes or neural progenitors
is essential for proper cell-cell communication within the NVU and allows for normal
CNS development and homeostasis (14).

During a transformation event (red,

dotted arrows), the glioma cell either loses expression or function of αvβ8 integrin,
which leads to the inhibition of normal vascular homeostasis. This defect allows for
the exploitation of the cerebral blood vasculature resulting in an increase in tumor
grade and worse overall patient prognosis.
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Specific Aims
Integrins are cell surface receptors for various ECM ligands that play roles in
cell adhesion and signaling pathways.

Improper integrin function regulation is

known to lead to the development of many CNS diseases, together with cancer.
Glioblastoma multiforme (GBM) remains the most frequently diagnosed and
malignant form of adult brain cancer. Despite recent progress in cancer diagnosis
and treatment, the median survival rates of patients have not changed over the past
several decades. Integrins have been shown to play fundamental roles in GBM
proliferation

and

malignancy.

The

main

pathological

hallmarks

include

pseudopalisading necrosis, increased mitotic index and microvascular proliferation
associated with vascular hemorrhage, edema and thrombosis. A gap in knowledge
exists between these pathologies and the molecular pathways driving them.
Consequently, we have initiated studies to investigate how the role of a specific
integrin, αvβ8, functionally contributes to blood vessel abnormalities in GBM.
Therefore, we hypothesize that abnormal αvβ8 integrin expression
and/or function contributes to the angiogenesis pathologies in malignant
brain tumors. To test this hypothesis, the following specific aims were developed:
1) Determining functional roles for αvβ8 integrin in glioma-induced
angiogenesis using an orthotopic mouse model of astrocytoma
2) Elucidate the functional roles for αvβ8 integrin in glioma-induced
angiogenesis during the pathogenesis of human gliomas
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CHAPTER 2:
Materials and Methods

Transgenic & Immunocompromised Mice
β8+/- mice (44) were obtained from the Mutant Mouse Regional Resource
Center (Portland, ME). Mice were backcrossed for several generations onto an
ICR/CD-1 mixed genetic background (Jackson Laboratories). β8 heterozygote’s
were crossed to generate β8+/+, β8+/- and β8-/- progeny.

Genotypes of the

progeny were confirmed by PCR using ear snips. Genomic DNA was isolated by
digesting ear snips in 100 µg/ml proteinase K (USB Scientific, Cleveland, OH) in
STE overnight at 55°C. Next, the mixture is added to the same volume of 100%
EtOH where the DNA precipitates out of solution and is dissolved for 30 minutes at
37°C in 1X TE while being shaken at 1400 RPM. The following PCR primers were
used to confirm β8 status, as previously described (44):
Wild-type primers:
1) 5′ATTATCTGGTTGATGTGTCAGC3′
2) 5′AGAGAGGAACAAATATCCTTCCC3′
Mutant primers:
1) 5′AGAGGCCACTTGTGTAGCGCCAAG3′
2) 5′GGAGGCATACAGTCTAAATTGT3′
Neo PCR conditions were as follows using Mango-Taq (Bioline, Taunton, MA):
Denature - Step 1: 95°C for 5’
Denature - Step 2a*: 95°C for 45”
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Annealing - Step 2b*: 58°C for 30”
Extension – Step 2c*: 72°C for 1’
*Repeat Steps 2a-c, 30 times
Extension – Step 3: 72°C for 10’
PCR Products:
Wild-type: 330 base pairs
Mutant (neo cassette only): 450 base pairs
Heterozygote: Both 330 and 450 base pair products

Male NCRnu/nu mice were purchased from Jackson Laboratories (Bar Harbor, ME)
and used for all experiments involving intracranial injections of transformed mouse
cells and human glioma cell lines.

Isolation and Purification of Primary Astroglia
Wild type and β8-/- neonatal (P0-P3) brains were removed and immersed in
sterile, cold Hank’s Balanced Salt Solution (HBSS). Olfactory bulbs and hindbrain
are snipped away from the cerebral cortices. The neocortices were dissected from
the hippocampus and other internal structures. Meninges were carefully removed
away from the freshly isolated cortices and minced in fresh HBSS.

The

homogenized cortices were double-checked for residual meninges and then
allowed to digest in 150 units/ml collagenase (Worthington, Lakewood, NJ) and 40
µg/ml DNAse I (Sigma, St. Louis, MO) in HBSS for 30 minutes at 37°C. The cortical
tissue was pelleted and triturated using a glass borosilicate pipette tip in low
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glucose DMEM (Sigma, St. Louis, MO) supplemented with 10% FCS (Hyclone,
Logan, UT) and passed through a 50 µm sterile filter. The single-cell mixture was
plated onto a tissue culture flask that was coated in 10 µg/ml murine laminin
(Sigma, St. Louis, MO) and allowed to grow for 7-10 days at 37°C/5% CO2. Once
the flask was confluent, the contaminating neurons, oligodendrocytes and
fibroblasts were shaken off of the astroglial monolayer overnight at 250 RPM at
37°C. Next day, the media was changed and astroglia were solely left behind
evident by their robust GFAP staining pattern (>95%+). All as previously described
(36).

Immortalization and Transformation of Murine Astroglia
To generate retroviral stocks, 293T Phoenix cells were transfected with
pLXSP-puro-E6/E7 and pLXSN-neo-G12VH-Ras (80). Primary astroglial cells were
transduced with the E6/E7 retroviral supernatant and cells were selected in growth
media containing 1 mg/ml puromycin for 5 days. Puromycin-resistant clones were
pooled and transduced with

G12V

H-Ras retrovirus supernatant, and selected after 10

days in G418 (900 mg/ml). To analyze integrin expression in passaged cells, semiconfluent monolayers of cells were trypsinized and split 1:5 onto new dishes. After
reaching 80-90% confluence the procedure was repeated.

Isolation of Primary GBM Cell Lines
Dr. Frederick Lang resected the primary GBM tissue sample from patients at
M.D. Anderson Cancer Center. The tissue was placed in phosphate buffered saline
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(PBS) and put on ice. Tissue was brought into the lab and minced. Homogenized
tissue was digested in the same collagenase/DNAse I solution in HBSS for 30
minutes at 37°C. The resulting tissue was pelleted and triturated in nude DMEMF12 (Mediatech, Manassas, VA) with a glass borosilicate pipette and passed
through a 50 µm filter. This single-cell suspension was grown in a T-75 flask in
DMEM-F12 with B-27 supplement and 20 ng/ml of EGF and bFGF (Invitrogen,
Carlsbad, CA). Upon spheroid formation, accutase (Sigma, St. Louis, MO) was
used to passage the cells.

Adherent Human Cell Lines and Culture Conditions
U87, LN18, and LN229 cell lines were purchased from ATCC (Manassas,
VA). U251 cells were kindly a gift of Dr. Oliver Bögler and SNB-19 cells were a kind
gift of Dr. Dimpy Koul, both at MDACC. All cell lines were grown in DMEM/F12
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum and
antibiotics. Normal human astrocytes were purchased (Lonza) and grown in their
proprietary media. Transformed human astrocytes were kindly donated to us from
Dr. Russel Pieper at UCSF.

Intracranial injections of Transformed Astroglia and Human Glioma Cell Lines
Nude mice were anesthetized and a single incision was made from the
anterior pole of the skull to the posterior ridge. A hole was drilled over the target
brain structure to expose the brain. We targeted the striatum for cell implantation
using the following stereotactic coordinates, all relative to the bregma: 1.5 mm
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rostral, 1.5 mm anterior, and 4 mm below the pial surface. An automated
micropump (Stoelting Instruments) was used to dispense cells in 3 to 5 ml PBS over
a five-minute period.

Transformed mouse astroglia cultured for less than four

passages after transformation were used for the experiments. In the Kaplan-Meier
survival studies 2.5 x 104 transformed mouse cells and 5 x 104 transformed human
astrocytes were injected, and animals were monitored until development of tumorinduced neurological phenotypes, ranging from weight loss to ataxia. In other
experiments, nude mice were stereotactically injected with 1-5 x 105 wild type or β8/- transformed cells and tumor-bearing animals were perfused with 4% PFA/PBS.
Brains were coronally sliced at 1 mm intervals and paraffin-embedded tissue was
serially sectioned at 7 mm intervals. Human intracranial xenograft tumors were
generated by injecting 5 x 105 U87 or SNB19 cells into the striatum of
immunocompromised mice.

Rescuing β8 Integrin Expression in β8-/- Transformed Astroglia and U87 Cells
Transformed β8-/- astroglia and U87 human glioma cell lines were transfected with
empty vector (pcDNA4.0-V5) or vector containing the full-length human β8 integrin
cDNA (pcDNA4.0-β8V5) (36). Stable transfectants were selected in zeocin (300
µg/ml) for 10 days, and integrin overexpression was confirmed by immunoblotting
lysates with anti-β8 or anti-V5 antibodies.

Isolation of CD31+ Intratumoral Endothelial Cells
Mice harboring 21 day-old intracranial tumors derived from β8-/- (+ vector) or
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β8-/- (+ β8V5) transformed astroglial progenitors were sacrificed. Tumors were then
microdissected from the brain and dissociated into a single cell suspension using
neural tissue dissociation media (105). CD31-expressing cells were sorted using a
rat anti-mouse CD31 antibody (BD Biosciences), magnetic beads coated with goat
anti-rat secondary antibody (Miltenyi Biotec, Inc.), and a BioMag magnetic
separation unit (Polysciences, Inc.)

Antibodies

for

Immunofluorescence,

Immunohistochemistry

and

Immunoblotting
An affinity-purified anti-αv rabbit polyclonal antibody was generated by our
group using a synthetic peptide (CKRVRPPQEEQEREQLQPHENGEGTSEA)
corresponding to a region of the chicken αv cytoplasmic domain. The anti-β8
integrin antibody used for all immunoblotting has been described previously (36,
50). The following antibodies were purchased: rabbit anti-β1 integrin, rabbit anti-β5
integrin, rabbit anti-nestin, and rat anti-mouse CD133 (Chemicon), rat anti-mouse
CD34 mAb (Genetex), chicken anti-Nestin IgY (Neuromics), rat anti-mouse CD31
and rat anti-mouse αv-PE mAbs (BD Biosciences), Texas-Red conjugated antiPhalloidin, rabbit anti-β-actin pAb, mouse anti-laminin (Sigma), rabbit anti-GFAP
pAb (DAKO), rabbit anti-pSmad3 mAb (Epitomics), rabbit anti-GFP (Abcam) and
anti-Ras and anti-E7 antibodies (Santa Cruz Biotech). Mouse anti-VEGF, rabbit
anti-Desmin, as well as rabbit anti-pSmad2 and tSmad2/3 antibodies were
purchased from Cell Signaling Technologies. The anti-V5 mAb was purchased form
Clontech Laboratories. Secondary antibodies were goat anti-rabbit, goat anti-
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chicken, goat anti-rat and goat anti-mouse, all conjugated to Alexa488 or Alexa594
(Molecular Probes). Secondary HRP-conjugated sheep anti-mouse, goat anti-rabbit
and

donkey

anti-chicken

IgY

antibodies

were

purchased

from

Jackson

Immunoresearch Labs. For quantitation of blood vessel densities, digital images
were captured from sections stained for CD34 immunofluorescence. Mean
fluorescence intensity was calculated using ImageJ software. Two investigators,
who were blinded to the genotypes for each sample, analyzed fluorescent sections.

Cell Surface Biotinylation of Integrin Subunits
Cells were grown to confluence in normal growth media. First, cells were
washed once with PBS.

Next, cell monolayers or GBM neurospheres were

incubated in 0.1 mg/ml of EZ Link Sulfo NHS LC biotin for 30 minutes at 37°C. After
the incubation, the cells were washed twice with PBS and once with TBS. Cells
were then lysed in NP40 Lysis buffer + protease inhibitors for 15 minutes at 4°C.
Next, mixture was centrifuged at high speed for 15 minutes at 4°C, after which
being assayed for protein concentration.

For each integrin subunit analyzed, a

proper same-species IgG control was used. Lysates were split evenly, in terms of
protein concentration, among the integrin subunits that were being assayed.
First, lysates were blocked with the 2°-agarose beads (pre-mixed with NP40
lysis buffer) for 30 minutes at 4°C while tumbling. Next, mixture was centrifuged at
1000xg for 1 minute at 4°C. Blocked lysates were removed and put into a fresh,
chilled microfuge tube with their respective primary antibody and tumbled overnight
at 4°C. Next day, 2°-species specific agarose beads are added to each incubating
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lysate for 45 minutes tumbling at 4°C. Mixtures were centrifuged and supernatant is
removed. Agarose bead containing integrin subunit was washed three times for 15
minutes while tumbling at 4°C. After the last wash, agarose pellets were incubated
with 2X SDS-PAGE, non-reducing, gel loading buffer for 10 minutes at 95°C.
Supernatant samples were run on a 7.5% SDS-PAGE gel, transferred onto PVDF
and blocked with 5% BSA. Next, membranes were incubated with ABC complexes
(chromagen) for 30 minutes. Then, membranes were thoroughly washed twice with
TBST for 10 minutes followed by a 10-minute wash with TBS. Afterwards, westerns
were visualized via chemiluminescence substrates.

Immunoblotting
Cells were lysed in either NP40 buffer + protease inhibitors (for nonphosphorylation-related experiments) or RIPA buffer + protease inhibitors &
phospho-protease inhibitors (for phosphorylation-related experiments) and proteins
were quantified via BCA assay (Pierce). 10µg of total protein was separated by
SDS-polyacrylamide gel electrophoresis and transferred to Immobilon P transfer
membrane (Millipore). The membranes were washed in Tris-HCl-buffered saline
(10 mM Tris-HCl, 150 mM NaCl, pH 8) + 0.1% Tween20 (TBST). Next, membranes
were blocked in 5% nonfat milk in TBST for 1 hour at room temperature. Blots were
probed overnight in 5% nonfat milk with specific antibodies at relevant dilutions (see
Antibodies section).

Blots were washed three times with TBST for 5 minutes.

Proper species-specific secondary antibodies conjugated to horseradish peroxidase
were diluted 1:1000 in 5% nonfat milk and incubated with the blots for 1 hour at
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room temperature. Again, blots were washed three times with TBST and developed
with chemiluminescence substrates.

β-actin antibody (1:5000) was used as a

loading control (Sigma).

Immunostaining
Frozen Samples
Animals were anesthetized and cardiac perfused with 4% paraformaldehyde
(PFA) in PBS.

Brains were removed and sliced at 2mm coronal sections and

placed into fresh 4% PFA for 2 hours at 4°C. Next, sections were placed in 9%
sucrose for 2 hours followed by an overnight incubation in 18% sucrose at 4°C.
Sections were then placed into OCT and frozen on dry ice and stored in -80°C. The
MDACC histology core performed sectioning onto positively charged slides and
H&E staining of resulting sections.
Paraffin Samples
Animals were anesthetized and cardiac perfused with 4% paraformaldehyde
(PFA) in PBS. Brains were removed and post-fixed overnight in 4% PFA at 4°C.
Next day, 2mm coronal section and placed into histology cassettes and submitted to
MDACC’s histology core for processing and standard paraffin embedding. 7 µmunstained sections were processes and 1 was H&E-stained.
Immunofluorescence (frozen)
Frozen slides were removed from -80°C and allowed to thaw to room
temperature for 20 minutes. Samples were rehydrated with PBS for 5 minutes.
Blocked for 30 minutes at room temperature in 10% serum of the species that the 2°
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antibodies were created (PBS).

Next, primary antibodies were diluted in the

blocking solution per manufacturers’ spec sheet overnight at 4°C.

Next day,

sections were washed twice with PBS +0.1% Tween20 for 5 minutes each followed
by a single wash with PBS for 5 minutes. Secondary antibodies conjugated to
AlexaFluor 488 or 594 were diluted in 10% blocking solution (1:250) and added to
the sections for 1 hour at room temperature followed by the same washing
procedure. Sections were then mounted in VectaShield mounting media + DAPI
and visualized on a Zeiss microscope. This process was also performed on paraffin
sections, see augmented protocol below.
Immunostaining (Paraffin)
Paraffin sections were placed on a 60°C heat block for 30 minutes. Sections
were then de-paraffinized in standard xylene/alcohol solutions.
rehydrated in with PBS.

Sections were

Slides were them submersed in either of two antigen

retrieval solutions, 1) Citrate, pH=6 or 2) Targeted Antigen Retrieval, pH=9 (DAKO)
and incubated at 95°C for 30-45 minutes.

Sections were cooled to room

temperature. Samples are rehydrated with PBS for 5 minutes.

Blocked for 30

minutes at room temperature in 10% serum of the species that the 2° antibodies
were created (PBS). Next, primary antibodies were diluted in the blocking solution
per manufacturers’ spec sheet overnight at 4°C. The following day, sections were
washed twice with PBS +0.1% Tween20 for 5 minutes each followed by a single
wash with PBS for 5 minutes.

Next, sections were blocked for endogenous

peroxidases with 0.3% hydrogen peroxide in PBS for 10 minutes. Then, sections
were washed three times with PBS. Sections were incubated in biotin conjugated
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secondary antibodies for 1 hour. Sections were washed twice with PBS +0.1%
Tween20 for 5 minutes each followed by a single wash with PBS for 5 minutes.
Then, sections were incubated in ABC chromagen (Vector) complexes for 30
minutes.

Sections were washed three times in PBS followed by DAB peroxidase

substrate incubation (Vector) for about 5-10 minutes. Next, sections are rinsed in
water and counterstained with hematoxylin (Vector). Finally, sections are mounted
with a xylene-based mounting medium (Richard Allen Scientific).
Immunocytochemistry (Coverslips)
Glass coverslips were coated with 10 µg/ml murine laminin cultured from
murine sarcoma basement membrane (Sigma) for 1 hours. Coverslips were rinsed
twice with PBS and 25,000 – 100,000 cells were plated per well. Once cells grew to
the desired confluence, they were rinsed once with PBS and then fixed on ice with
4% PFA for 10 minutes.

Next, coverslips were washed again with PBS and

permeabilized with PBS + 0.5% NP40 for 10 minutes at room temperature.
Coverslips were washed with PBS and blocked in 10% serum of the species in
which the secondary antibody was produced. After blocking, primary antibody was
incubated atop the coverslip overnight at 4°C. Next day, coverslips were washed
twice with PBS +0.1% Tween20 for 5 minutes each followed by a single wash with
PBS for 5 minutes. Coverslips were incubated in fluorescent-conjugated secondary
antibodies and mounted in vectashield mounting medium + DAPI and imaged under
the Zeiss microscope.
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Fluorescence Activated Cell Sorting (FACS)
Green fluorescence protein (GFP) sorting
Primary GBM cell lines and transformed human astrocytes were transduced
with lentiviral constructs were washed with PBS and detached with trypsin
(adherent cells) or accutase (neurospheres). Cells were sorted by MDACC’s FACS
core facility on the BD FACS ARIA flow cytometer (BD Biosciences).

GFP+

populations were sorted and used in various experiments.
Traditional FACS
Various cell types were washed with PBS and incubated in a Phycoerythrin
(PE)-conjugated αv-recognizing antibody and/or an Allophycocyanin (APC)conjugated CD133-recognizing antibody (~10µL/106 cells) for 30 minutes on ice in
the dark. Proper IgG-isotype and mock controls were performed to validate primary
antibody’s specificity. Next, cells were washed with a FACS wash buffer (2% FBS
or BSA, 2mM EDTA, 1% antibiotics in PBS) twice. PE/APC-labeled cells were then
sorted on the BD FACS ARIA flow cytometer by the MDACC core facility. Analysis
was focused on evaluating αv integrin expression in specific cell types as well as
sorting αv high and low, and in some instances CD133+, populations for intracranial
injection.

In vitro Proliferation Assay
Cells were plated at 25,000 cells/well into 12 well plate, each cell type were
performed in triplicate. Using trypan blue exclusion solution and a hemocytometer,
cells were counted at 24, 48, 72 and 96 hours post-plating.
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Soft Agar Assays
A 1% solution of sterile DNA-grade agarose was mixed with 2X DMEM
medium, and the 1X base solution was added to 6-well dishes and solidified. The
transformed mouse and human astroglia (20,000 cells/ml in 2X media) were mixed
with a 0.7% agarose solution, and 5,000 cells were added to the base agarose. The
plates were incubated at 37°C for 14 days. Cells were fixed with 4% PFA/PBS,
stained with 0.1% crystal violet and mean colonies were counted.

Luciferase Reporter Assays
Mink lung epithelial cells stably transfected with a PAI1-Luciferase plasmid
(106) were seeded onto poly-lysine-coated 6-well plates at 4x105 cells per well.
Twelve hours later media was removed and serum-free media was added for 24
hours. Conditioned media from wild type and β8-/- transformed astroglial progenitor
cells pre-incubated for 12 hours with or without 10 ng/ml LAP-TGFβ1 (R&D
Systems) was collected and added to MLECs for 12 hours. Cell lysates were then
prepared and luciferase substrates were added and quantified using an Enhanced
Luciferase Assay Kit (BD Biosciences).

Semi-quantitative Reverse Transcriptase PCR (RT-PCR)
RNA/cDNA Preparation
Cells were harvested and 0.5 ml of Trizol reagent (Invitrogen) was added and
pipetted up/down.

This mixture incubated for 10 minutes at room temperature.

Next, mixture was centrifuged for 10 minutes in the cold room. The soluble fraction
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was transferred to a new microfuge tube and to it 100µL of chloroform was added,
homogenized and incubated at room temperature for 10 minutes. Next, mixture
was centrifuged for 15 minutes in the cold room. The top phase was transferred to
a fresh microfuge tube where 250µL of isopropanol was added for 10 minutes at
room temperature. Samples were centrifuged and the supernatant was removed
left with the RNA pellet. The pellet was washed with 70% EtOH followed by another
centrifugation step. The pellet was dried with a vacuumfuge and dissolved in 50µL
of water. Next, absorbance readings determined the concentration of the cRNA.
5µg of cRNA was used to produce cDNA according to protocols of
SuperScript II Reverse Transcriptase kit (Invitrogen). Resulting cDNA was treated
with RNAse A to remove any residual cRNA in the sample.
In vitro analysis of TGFβ gene expression (cDNA)
The expression of TGFβ isoforms was determined by RT-PCR.
following primers were used to look at three TGFβ isoforms:
TGFβ1
(Forward) 5’-GCTACTGCCGCTTCTGCT-3’
(Reverse) 5’-GCCCTGTATTCCGTCTCC-3’
TGFβ2
(Forward) 5’-TACTACGCCAAGGAGGTT-3’
(Reverse) 5’-AATTATTAGACGGCACGAA-3’
TGFβ3
(Forward) 5’-GCAAAGGGCTCTGGTAGT-3’
(Reverse) 5’-GTCTCCATTGGGCTGAAA-3’
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The

The primers along with the Platinum Taq DNA Polymerase High Fidelity kit
(Invitrogen) were used to determine isoform expression.

GAPDH cDNAs were

amplified by PCR in the same reaction mixture and carried out by an initial
denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30
seconds, annealing at 55°C for 30 seconds, and extension at 68°C for 1 minute. A
final elongation step was carried out at 68°C for 10 min.
Vascular Endothelial Growth Factor A (VEGF-A) gene expression
cDNAs were generated in the same way as for the TGFβ isoform studies.
VEGF-A isoforms were amplified by RT-PCR using primers in the mouse VEGF
cDNA amplification kit (R&D Technologies). Kit positive controls were amplified by
PCR in the same reaction mixture and carried out by an initial denaturation at 94°C
for 5 min, followed by 35 cycles of denaturation at 94°C for 45 seconds, annealing
at 55°C for 45 seconds, and extension at 72°C for 45 seconds. A final elongation
step was carried out at 72°C for 10 min. The kit produces bands at 613, 541 and
410 basepairs for VEGF-188, -165 and -120, respectively. Positive control product
size is 235 bp.

Lentiviral shRNA Cloning/Transduction
For lentiviral-mediated stable knockdown of human β8 integrin, DNA
oligonucleotides were synthesized (Integrated DNA Technologies) to generate
shRNA stem loops. Three separate regions of the human β8 integrin cDNA were
targeted. The following three sequences were BLAST-searched to confirm minimal
homology with other genes (bold=loop):
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1: 5’-GCAAAGGCTGCTCAGTTGATTCAAGAGATCAACTGAGCAGCCTTTGC-3’
-

Targets the 3’ β8 ORF

2: 5’-GTATGGCATACCTACAGGGTTCAAGAGACCCTGTAGGTATGCCATAC-3’
-

Targets the 5’ β8 ORF

3: 5’-GCAAAGGCTGCTCAGTTGATTCAAGAGATCAACTGAGCAGCCTTTGC-3’
-

Targets the β8 UTR

Three separate regions of the human αv integrin cDNA were targeted.

The

following sequences were BLAST-searched to confirm minimal homology with other
genes (bold=loop):
1: 5’-GTCCCATCAGTGGTTTGGATTCAAGAGATCCAAACCACTGATGGGAC-3’
-

Targets the 3’ αv ORF

2: 5’-GTTGGCAGATCTTCCTAAGTTCAAGAGACTTAGGAAGATCTGCCAAC-3’
-

Targets the 5’ αv ORF

3: 5’-GAGGAGTCTCGAGTCCTGATTCAAGAGATCAGGACTCGAGACTCCTC-3’
-

Targets the αv UTR

Non-Targeting (NT) Sequence (provided by Bar-Eli lab lentiviral core):
5’- TTCTCCGAACGTGTCACGT-3’
The αv and β8 oligonucleotides were annealed into the pLB lentiviral genetransfer vector (107), using the HpaI and XhoI restriction sites.

Highly competent

E. coli (DH5α – Invitrogen) were transformed with the annealed lentiviral vector and
grown overnight at 37°C on ampicilin-resistant LB-agar. Many bacterial colonies
were isolated and grown in LB-broth (+amp) overnight at 37°C at 225 RPM. DNA
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was isolated from the bacteria via a Midi plasmid DNA purification kit (Qiagen).
Lone Star DNA sequencing company verified proper insertion and lengths of
inserts. Lentiviruses were produced by transfecting 293-FT cells with pLB transfer
vectors (αv, β8 and NT) in combination with plasmids encoding gag/pol and VSV-G
envelope proteins. Next day, the media is changed and fresh growth medium is
added. The following day, lentiviral media is harvested, filtered to remove cellular
debris and concentrated using centrifugation concentrators (Fisher). Appropriate
cells are plated at 50-70% confluence into 6 well plates and transduced with the
lentivirus + polybrene (Sigma) overnight.

Next day, viral-containing medium is

aspirated off and fresh normal growth media is added. Knockdown is verified via
western blot. A target of 70% or higher knockdown is most desirable.

Invasion Assays
Matrigel invasion assay chambers (BD - 8µM pores) were pre-incubated in
media containing no chemoattractant. 10% FBS in normal growth medium was
added to the lower well to act as the chemoattractant for the 50,000 cells
transformed human astrocytes plated above the Matrigel-coated insert. Invasion
occurred over a 24 hour period at 37°C. Next day, the inserts were removed, the
matrigel swabbed away and the invaded cells on the opposite side from their initial
placement were stained with crystal violet. The stain was solubilized in 2% SDS
and an absorbance reading at OD=570nm was measured.
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Live Migration Assays
Transformed human astrocytes were plated at 100,000 cells/well onto murine
laminin coated coverslips. At 100% confluence, with a p-10 pipette tip, a wound or
scratch was made down the middle of the coverslip. Over 36 hours, at increments
of 30 minutes, pictures were taken with the Olympus Inverted Imaging Microscope.
Movies were visualized and migration rates were determined.

VEGF/TGFβ ELISAs
300,000 cells were plated into 6-well plates at the same densities and were
allowed to condition the media for 48 hours.

Each cell type was assayed in

triplicate. Media was harvested and filtered to remove cellular debris. Kit and
unconditioned medias were used as controls. Colormetric ELISAs were used to
quantify VEGF (R&D Systems) and TGFβ (eBioscience) presence in conditioned
medias.

Statistical Analyses
Student’s t-test was used to determine statistically significant differences.
The Wilcoxon Rank Sum Test was used for analysis of Kaplan-Meier survival
results.
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CHAPTER 3: Specific Aim 1

Determining Functional Roles for αvβ8 Integrin in Glioma-Induced
Angiogenesis using an Orthotopic Mouse Model of Astrocytoma

Introduction
Grade IV astrocytomas, or glioblastoma multiformes (GBMs) are the most
common and fatal form of primary brain cancer and are noted for their hallmark
angiogenic pathologies (108). More specifically, blood vessels in GBMs exhibit
endothelial cell hyperplasia, glomeruloid-like tufts, and show signs of edema and
hemorrhage owing to the breakdown of the intratumoral blood brain barrier (102).
Over the last several decades, the median survival rate for GBM-diagnosed patients
has remained at 9-12 months (57) due to the poor efficacy of standard clinical
intervention (55).
Our laboratory has shown previously that αvβ8 integrin is a key regulator of
angiogenesis in the embryonic mouse brain (35, 36, 44, 52, 109). Upon genetic
ablation of αv or β8 integrin genes in neural progenitors and astrocytes, but not
endothelial cells, intracranial vascular phenotypes develop as a result of defective
integrin-mediated activation of LAP-TGFβs (33, 49). Combined TGFβ1 and TGFβ3
loss leads to severe intracerebral hemorrhage, similar to those vascular pathologies
identified in αv and β8 integrin knockout mouse models (110).

Consequently,

conditional deletion of TGFβRII on Alk1-positive endothelial cells leads to similar
brain-specific vascular pathologies (Paul Oh, University of Florida College of
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Medicine). Collectively, these models identify the αvβ8 integrin-TGFβ axis as a key
regulator of brain angiogenesis in which genetic ablation of any component leads to
intracranial-specific vascular pathologies commonly observed in GBM.
Thus, we hypothesized that abnormal αvβ8 integrin expression and/or
function contributes to the angiogenesis pathologies in malignant brain tumors.
Herein, a mosaic mouse model of astrocytoma was developed to elucidate the
functional roles for αvβ8 integrin in glioma-induced angiogenesis.
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Results
Isolation of Primary Astroglia from Wild Type and β8-/- Mice
Primary astroglial cells were cultured from neonatal (P0-P3) wild type (+/+)
and β8 integrin homozygous (β8-/-) mutant mice from cerebral cortices. Neonatal
β8-/- mice exhibited distinctive intracerebral hemorrhage (Figure 7c) as compared
to wild type (Figure 7a) mice, thus making them easily distinguishable. In addition,
mice were genotyped via PCR utilizing genomic tail DNA as previously described
(44).

Cells were grown on dishes coated with laminin, a basement membrane

protein known to support neural stem and progenitor cell proliferation (111). The
majority of wild type and β8-/- astroglia expressed the astrocytic and sometimes
neural progenitor marker (112), glial fibrillary acidic protein (GFAP) (Figure B, D
upper panel) while nearly 100% of the cells expressed robust levels of Nestin, a
marker for neural progenitors within the brain (Figure 7b, d middle panel) (113). Colocalization of GFAP and Nestin reveals nearly 100% overlap (Figure 1b, d lower
panel). To verify integrin expression, both wild type and β8-/- primary astroglial cell
surfaces

were

labeled

with

an

amine-reactive

derivative

of

biotin.

Immunopreciptation with integrin-specific antibodies was performed showing robust
levels of both αvβ5 and αvβ8 integrins expressed on wild type primary astroglia
(Figure 7e, left panel), similar to the integrin profile of primary human astrocytes
(49). The β8-/- cells express αvβ5 integrin, but not αvβ8 integrin (Figure 7e, right
panel) due to the genetic ablation of the β8 integrin gene. Both cell lines also
express robust levels of αvβ3 and αvβ1 (data not shown). Wild type and β8-/-
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primary astroglial proliferation rates were quantified over a 96-hour period
identifying no obvious differences.
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Figure 7: Wild Type and β8-/- Primary Astroglia
Wild type (A) and β8-/- (C) postnatal day 1 whole brains are distinguishable
based on the hemorrhage throughout knockout brain. Wild type (B) and β8-/- (D)
neonatal primary astroglia are microdissected from cerebral cortices.

Both cell

types express similar levels of GFAP (B, D upper panels) and Nestin (B, D middle
panels), displaying high co-localization (B, D lower panels).

(E) Cell-surface

analysis of integrin expression on wild type and β8-/- primary astroglia.
Biotinylation and immunoprecipitation reveals the lack of αvβ8 integrin expression in
β8-/- primary astroglia. (F) αvβ8 integrin expression status does not alter in vitro
proliferation rates of primary astroglia (n=3/timepoint) at 24, 48, 72 and 96 hours
post-plating.
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Immortalization and Transformation of Wild Type and β8-/- Primary Astroglia
Nestin-positive primary wild type (Figure 8a, upper panel) and β8-/- (Figure
8a, bottom panel) astroglia were transduced with a retrovirus expressing human
papilloma virus (HPV) E6 and E7 proteins (80), thus immortalizing them (Figure 8d,
middle panel). The E6 oncoprotein ubiquitinates p53, a major tumor suppressor,
and sends it to the proteosome for degradation while E7 inhibits the association of
pRB with the E2F transcription factor allowing for uncontrolled cell cycle progression
(Figure 8c) (114). p53 and pRb functions are often abrogated in human gliomas
(108, 115). Next, immortalized astroglia were transformed by a second retroviral
transduction producing an oncogenic version of H-Ras (G12VH-Ras) (80) (Figure 8d,
upper panel) as Ras function is often elevated in the glioma setting, either via gene
mutations or increased expression of other upstream tyrosine kinases (65). While
nestin expression did not change among primary and transformed astroglial
populations, the transformed morphologies certainly appeared smaller, spindled and
elongated as compared to their primary form (Figure 8a,b).
Upon transformation of the wild type and β8-/- primary astroglia, we
observed a substantial gain in CD133/Prominin 1 expression (Figure 9a, lower
panel; 9b 2nd panel), a transmembrane protein commonly expressed in embryonic
neural stem cells (116), GBM and other solid tumors (57, 117). Any expression of
GFAP in the primary astroglia was completely lost post-transformation (Figure 9a,
top panel; 9b, 3rd panel), although nestin expression remained ubiquitous among
the cell lines (Figure 9a, middle panel; 9b, 1st panel). CD133/Prominin 1’s increase
in expression coupled with GFAP loss tends to suggest that upon transformation,

	
  

57	
  

these astroglia are becoming ‘de-differentiated’, commonly observed by others upon
oncogenic transformation (115, 118).
Lastly, in vitro evaluation of the wild type and β8-/- transformed astroglia was
necessary to assess the necessity of αvβ8 integrin for proliferation and growth
anchorage independence. Firstly, proliferation rates were analyzed over a 96-hour
time period (n=3/cell line) showing no obvious differences (Figure 10a). Secondly,
a classical assay was used to establish the doubly transduced astroglia as being
‘transformed,’ essentially evaluating the ability of the cells to form colonies in an
anchorage independent fashion, as non-malignant cells will not. Again, soft agar
colony formation did not differ among the wild type and β8-/- transformed astroglia
(Figure 10b).
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Figure 8: Malignant Transformation of Primary WT and β8-/- 1° Astroglia
Upon immortalization and transformation of wild type and β8-/- astroglia,
nestin expression is retained although transformed astroglia display a more
spindled morphology (A, B) (C) Scheme for two-step retroviral immortalization and
transformation of primary wild type and β8-/- astroglia. (D) Overexpression of
mutant HRas (G12V) and E7 oncoprotein whole cell lysates immunoblotted with
anti-Ras, E7 and β-actin antibodies.
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Figure 9: ‘De-differentiation’ upon Transformation of Astroglia
(A/B) Malignant transformation of wild type and β8-/- astroglia induces
suspected ‘de-differentiation’ evident by a loss of GFAP expression (A, upper panel
IF & B, GFAP immunoblot) and gain of CD133 expression (A, bottom panel IF & B,
CD133 immunoblot).

Nestin expression (A, middle panel IF & B, Nestin

immunoblot) remains ubiquitous among the cells lines. β-actin acts as a loading
control for the immunoblot.
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Figure 10:

Wild Type and β8-/- Transformed Astroglia in vitro Growth

Characteristics
(A) αvβ8 integrin expression status does not alter in vitro proliferation rates of
transformed astroglia (n=3/timepoint) at 24, 48, 72 and 96 hours post-plating. (B)
αvβ8 integrin expression status does not alter in vitro anchorage independence of
transformed astroglia in a soft agar colony formation assay (n=3/cell type).
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Oncogenic Transformation Reduces αvβ8 Integrin Expression
Due to the lack of specificity of all commercially available anti-β8 antibodies,
primary and transformed wild type and β8-/- astroglia were characterized for their αv
integrin cell surface protein expression via fluorescent activated cell sorting (FACS).
Among the primary cells, upwards of 90% of them expressed αv integrin (Figure
11a, upper plots).

Upon transformation, a two-fold reduction in cell surface αv

integrin expression was observed (Figure 11a, bottom plots).

Corroborating

evidence of the FACS data was established upon further analysis of whole cell
lysates from primary and transformed astroglia. The wild type cells lost upwards of
90% of their β8 integrin expression while also exhibiting a reduction in overall αv
integrin

expression

(Figure

11b,

top

two

panels).

Oncogenic-mediated

transformation did not promote an overall reduction in ‘global’ integrin expression,
as β1 integrin is ubiquitously expressed among the cell lines, both primary and
transformed (Figure 11b, 3rd panel).

Interestingly, upon wild type transformed

astroglia passaging, β8 integrin expression diminishes and was completely lost by
p10 (Figure 11c) while αv integrin expression decreased.

This was not a cell

culture artifact as primary wild type neurospheres cultured over 6 passages did not
lead to the same result (Figure 11d). Additionally, these neurospheres have been
passaged out to p10 (data not shown) exhibiting no change in αvβ8 integrin
expression.
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Figure 11: Reduced αvβ8 Integrin Protein Expression Post-transformation.
(A) Primary cells (top panel) and transformed cells (lower panel) were
analyzed by fluorescent-activated cell sorting using an anti-αv integrin phycoerythrin
(PE) antibody (% positive in red boxed areas). Sort reveals an approximate 50%
reduction in overall αv integrin cell-surface expression. (B) Lysates from primary
(prim.) and transformed (trans.) wild type and β8-/- astroglia were immunoblotted
with anti-αv, β8, and β1 integrin. β-actin acts as a loading control (same lysates
used in Figure 10). Note the progressive loss of both αv and β8 integrin proteins as
a result of oncogene transformation, while β1 integrin expression remains
ubiquitous. The lower band in the αv integrin blot most likely represents a nonglycosylated integrin isotype.

(C) Wild type transformed astroglia grown for 12

passages. P2-P12 lysates were immunoblotted with antibodies against αv and β8
integrins. β-actin acts as a loading control. Note the progression of αvβ8 integrin
loss as cells are passaged. (D) Primary neurospheres were grown for 6 passages
and no changes in αv or β8 integrin expression were evident. β-actin is as a loading
control.
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Figure 11
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Gross Analysis of β8 Integrin Expression in a Mosaic Mouse Model of
Astrocytoma
Due to evidence of diminished αvβ8 integrin expression beyond passage
four in wild type transformed astroglia (Figure 11c), we only used early passage
cells (p2-p4) in this study.

Wild type and β8-/- transformed astroglia were

stereotactically injected into the striatum of immunocompromised mice to evaluate
their in vivo tumorigenicity. In the first set of injections, 500,000 wild type and β8-/transformed astroglia were implanted and allowed to proliferate for 21 days
(n=20/cell line). The tumor bearing mice were anesthetized and cardiac perfused to
flush out any of the properly functioning vessels and to attain a better fix of the brain
tissue. After a 24-hour post-fix, brains were coronally sliced at 1mm increments.
There were clear macroscopic differences among the appearances of the wild type
and β8-/- astrocytomas (Figure 12a, b). While all mice injected developed tumor,
only two of the 20 wild type astrocytomas developed gross intratumoral hemorrhage
while nearly all β8-/- tumor bearing mice (17/20) exhibited it.
A Kaplan-Meier survival study evaluated the overall effect of wild type (n=20)
and β8-/- (n=16) tumor bearing animals where 25,000 cells were injected into the
same location. Tumors were allowed to grow until the mice succumbed to tumor
burden. β8-/- tumor bearing animals survived significantly less than wild type tumor
bearing animals (Figure 12c). At 50% survival, β8-/- tumor bearing mice survived
26 days while wild type tumor bearing mice survived 33 days. The primary reason
for premature death of the β8-/- tumor bearing mice is most likely due to the severe
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intratumoral hemorrhage leading to cerebrospinal fluid blockage resulting in
hydrocephaly thus causing severe neurological defects.
In a separate set of experiments, 500,000 wild type and β8-/- transformed
astroglia were intracranially implanted into nude mice and tumor volume was
evaluated at 14 and 21 days post-injection (n=9/cell line/time point).

Tumor

volumes were assessed by measuring the largest cross-section of H&E-stained
tumor sections multiplied by the thickness of the coronal sections and how far the
tumor spanned the brain parenchyma. Although clear macroscopic pathologies and
a significant decrease in overall survival in β8-/- astrocytomas were obvious, tumor
volumes did not vary (Figure 12d).

	
  

66	
  

Figure 12: Severe Intratumoral Vascular Pathologies in β8-/- Tumor Bearing
Animals Cause Reduced Overall Survival.
(A) Wild type and (B) β8-/- tumor bearing mice were cardiac perfused and
sectioned at 1mm increments. Note the gross vascular pathologies in the β8-/tumors (arrows in B).

(C) Kaplan-Meier survival analysis reveals a significant

overall reduction in survival in β8-/- tumor bearing mice (n=16) versus wild type
tumor bearing mice (n=20) (*p<0.001 at 50% survival). (D) Athymic mice harboring
wild type and β8-/- astrocytomas were sacrificed at 14 days (n=9/genotype) and 21
days (n=8/genotype) after injection. No differences in tumor volume were observed
among the wild type and β8-/- astrocytomas.
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Microscopic Analysis of Wild Type and β8-/- Astrocytomas
Coronal sections of wild type and β8-/- astrocytomas were H&E-stained
revealing differences in the vascular make-up of these tumors. Wild type (Figure
13a) tumors were well-vascularized and displayed pathologies consistent with those
present in grade III anaplastic astrocytomas (119, 120).

However, β8-/-

astrocytomas displayed severe vascular pathologies including intratumoral
hemorrhage as well as vascular edema and thrombosis (Figure 13b). Pathologies
evident in knockout tumors are consistent with those hallmarks of grade IV GBMs
(55). Blood vessel immunostaining of wild type and β8-/- coronal astrocytoma
samples revealed CD34-positive vascular endothelial cells lining the intratumoral
vascular networks. β8-/- tumor-associated vessels (Figure 13d, f) were far more
distended and tortuous exhibiting signs of thickening of the vessel walls as
compared to those found in wild type tumors (Figure 13c, e).

Moreover, β8-/-

astrocytomas displayed significantly more microvascular density (MVD) than wild
type astrocytomas.

There were significantly more blood vessels per 200x field

(n=5/tumor type), assessed by tallying number of vessels (Figure 13h) and
quantifying CD34+ fluorescence (Figure 13g) in knockout tumors compared to wild
type tumors. Pericytes are vascular support cells fundamental for normal vascular
support and function (121).

Therefore wild type and β8-/- astrocytomas were

immunostained for desmin, a marker for pericytes, resulting in nearly all intratumoral
vascular networks exhibiting proper pericyte coverage (Figure 13e, f).
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Figure 13: Histological Analysis of Wild Type and β8-/- Astrocytomas.
Coronal sections of wild type (A) and β8-/- (B) astrocytomas were stained
with hematoxylin and eosin (H&E) and visualized microscopically (200x).

Note

severe vascular pathologies including intratumoral hemorrhage, edema and
thrombosis. Coronal sections of wild type (C) and β8-/- (D) astrocytomas were
immunostained with an antibody against vascular endothelial cells (arrows), CD34
(400x).

CD34 (green) and desmin (red), a marker for pericytes, merged

immunofluorescent images of coronal wild type (E) and β8-/- astrocytomas (200x).
Coronal

sections

of

wild

type

(E)

and

β8-/-

(F)

astrocytomas

were

immunofluorescently double-stained with CD34 (green, vessels) and desmin (red,
pericytes) (200x).

The areas boxed are magnified at the bottom right of these

images to illustrate the pericyte coverage of the CD34+ vessels.

(G) CD34

immunofluorescence intensity was quantified for wild type and β8-/- astrocytomas
(n=5/cell line). (H) Mean vessels were quantified per 200x field in wild type and β8/- astrocytomas.

Note both evaluations of vessel characteristics exhibited

significantly more vessel density and number in β8-/- astrocytomas versus wild type
astrocytomas (G, *p<0.001; H, *p<0.05).
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Figure 13
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Rescuing β8 Integrin Expression in β8-/- Transformed Astroglia
In order to confirm the vascular pathologies found in the β8-/- astrocytomas
were due to the genetic ablation of the integrin subunit, β8 integrin was
overexpressed in the β8-/- transformed astroglia. The cells were stably transfected
with a plasmid expressing human β8 integrin protein with a C-terminal V5 epitope
tag (β8-V5). Expression was verified by western blot with the β8-/- (+β8-V5) cells
displaying robust β8 integrin and V5 protein expression (Figure 14A).

β8-/-

transformed astroglia were stably transfected with empty pcDNA4.0 and
intracranially implanted into the striatum of athymic mice (n=5). Resulting tumors
recapitulated the overall macro- and microscopic vascular pathologies of the
untransfected β8-/- cells (Figure 14b, right panel). Conversely, upon injection of the
β8-/- transformed astroglia (n=5) stably restored with β8 integrin expression, β8-/astrocytoma pathologies were largely resolved evident by the loss of gross
hemorrhage (Figure 14b, left panel).

Vessel pathologies were restored in the

‘rescued’ tumors (Figure 14c, e) while tumor cells stably transfected with the empty
vector exhibited similar microscopic vascular pathologies evident in parental β8-/tumors (Figure 14d, f). In fact, the severe microvascular density evident in the
knockout tumors was significantly reduced in the β8 integrin expressing tumors as
assessed by CD34 immunofluorescence intensity quantitation (Figure 14g).
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Figure 14: Exogenous Expression of β8 Integrin Resolves β8-/- Astrocytomainduced Vascular Pathologies.
(A) β8-/- transformed astroglia were stably transfected with empty vector or vector
expressing human β8 integrin protein with a V5 C-terminal tag (β8-V5). Cell lysates
were immunoblotted against antibodies against β8 integrin (top panel) and V5
epitope tag (middle panel). β-actin (bottom panel) acts as a loading control. (B)
Athymic mice were intracranially implanted with β8-/- transformed astroglia
transfected with vector alone (right panel) or vector plus β8-V5 (left panel). Upon
tumor formation, mice cohorts were cardiac perfused and coronally section in 1mm
increments. Note the gross hemorrhagic pathology (arrows) in the vector alone β8/- astrocytomas is largely resolved by exogenous expression of β8 integrin. Coronal
sections from β8-/- (+β8-V5) astrocytomas (C) and β8-/- (+vector alone)
astrocytomas (D) were H&E-stained (200x). Note the dilated intratumoral blood
vessels in β8-/- (+vector alone) astrocytomas are resolved in tumors exogenously
expressing β8V5 integrin protein.

Coronal sections from astrocytomas were

immunofluorescently stained with CD34 (red) to reveal intratumoral blood vessels,
counterstained with a DAPI nuclei stain (blue) (200x). Note the clear differences in
vascular patterning in β8-/- (+β8-V5) tumors (E) compared to β8 -/- (+vector) tumors
(F). (G) CD34 immunofluorescence intensity was quantified to be significantly less
in β8-/- tumors exogenously overexpressing β8 integrin protein (*p<0.002).
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Figure 14
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Assessing the Mechanism Behind Severe β8-/- Tumor Vascular Pathologies
Integrin-dependent VEGF expression
Upon initial observation of the knockout tumor obvious vascular pathologies,
vascular endothelial growth factor (VEGF), consistent with literature involving the
growth factor with pathological hemorrhage and angiogenesis in glioma, was
considered to be mechanistically involved (99, 100, 122). Therefore, VEGF levels
were assessed at both the mRNA and protein level. Via semi-quantitative RT-PCR,
VEGF isoforms -164 and -120 mRNA levels were nearly non-detectable in the β8-/transformed astroglia as compared to wild type cells (Figure 15a). Furthermore, an
ELISA

showed

β8-/-

transformed

astroglia

conditioned

media

containing

significantly less soluble VEGF as compared to wild type cells (Figure 15b). Wild
type and knockout astrocytomas were microdissected from the normal brain
parenchyma and lysed (n=2/tumor type). Although in vitro analyses would suggest
reduced VEGF expression in vivo, there was no obvious difference in wild type and
knockout tumor lysates (Figure 15c). In addition, ex vivo VEGF analysis of both
tumor types via immunofluorescence further corroborated what was observed in
tumor lysates as no clear distinctions in overall VEGF expression could be
elucidated (Figure 15d, e).
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Figure 15: VEGF mRNA and Protein Status in WT and β8-/- Astrocytomas.
(A) VEGF mRNA expression analysis of wild type and β8-/- transformed
astroglia reveals reduced VEGF120 and VEGF164 isoforms in knockout
astrocytomas via semi-quantitative reverse transcription-PCR (RT-PCR). (B) VEGF
presence in conditioned media from wild type and β8-/- transformed astroglia was
analyzed via a VEGF ELISA (n=3/cell line). Note the significant reduction in VEGF
protein levels in β8-/- transformed astroglia conditioned media (*p<0.001).

(C)

Western blot analysis revealed no difference in intratumoral VEGF protein
expression in wild type and β8-/- transformed astrocytomas (n=2/genotype). β-actin
(bottom panel) acts as a loading control. Coronal sections of wild type (D) and β8-/astrocytomas were immunofluorescently stained for CD31 (vessels; arrows, red)
and VEGF (green) revealing no obvious differences in VEGF among the tumor
types.
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Figure 15
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αvβ8 integrin-mediated activation of TGFβ and signaling
αvβ8 integrin is expressed on normal human astrocytes where it has the
ability to bind the RGD tripeptide motif in latent-TGFβs allowing for their bioactivation. Furthermore, integrin-regulated activation of the inactive cytokine plays
fundamental roles in blood vessel homeostasis (49). TGFβ has been shown to be
involved in a wide range of physiologically normal and pathological cellular
processes, such as proliferation, apoptosis, and differentiation and more specifically
for this dissertation, critical roles in vascular development (112-114). In short, upon
TGFβ activation, the cytokine homodimerizes and targets its cognate receptor,
TGFβRII which then recruits and transphorylates TGFβRI leading to intracellular
signaling.

Downstream of the receptor complex, common receptor Smads (R-

Smads) 2 and 3 are phosphorylated and with the help of a co-Smad 4, enter the
nucleus and up regulate transcription of target genes (123).
Complete loss of TGFβ1 leads to embryonic lethality; therefore in order to
study the integrin-mediated activation of the cytokine, the Munger lab mutated the
RGD binding site for αvβ8 integrin to an RGE tri-peptide motif. Concomitant loss of
integrin-activated TGFβ1, via a RGE knockin mouse model, and complete loss of
TGFβ3 leads to acute intracranial hemorrhage, commonly observed in the complete
αv and β8 integrin knockout mice (110, 124) (Figure 3a-d; 16a). Moreover, upon
conditional deletion of TGFβRII on endothelial cells via an Alk1-Cre recombinase;
similar intracerebral hemorrhage was observed (Paul Oh, University of Florida
College of Medicine, unpublished data) (Figure 16c). Our lab conditionally deleted
TGFβRII on neural cells via a Nestin-Cre transgene and no phenotype was
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observed, therefore giving credence towards a αvβ8 integrin-dependent paracrine
role for cerebral vessel homeostasis (124).
Cambier and colleagues provided evidence for αvβ8 integrin’s role in the
bioactivation of latent TGFβs (49), therefore, we set forth to verify this phenomenon.
293-T cells were stably transfected with human β8 integrin protein or empty
pcDNA4.0 vector alone. Then, both stable cell lines were transiently transfected
with a TGFβ reporter plasmid containing a truncated plasminogen activator
inhibitor-1 (PAI-1L) promoter leading to firefly luciferase expression upon R-Smads
engagement (106). Endogenous production of latent TGFβs led to a significant
bioactivation upon 293T cells stably expressing human β8 integrin protein (Figure
16e). Exogenous addition of LAP-TGFβ1 caused an even more significant increase
in cytokine activation confirming the fundamental role of αvβ8 integrin-mediated
bioactivation of latent TGFβs (Figure 16e).
Next, a similar approach was taken to analyze TGFβ’s activation status
utilizing an in vitro two-cell based firefly luciferase reporter assay. Firstly, mink lung
epithelial cells (MLECs) were stably transfected with the same truncated PAI-1L
promoter plasmid (106). Wild type and β8-/- transformed astroglia were exposed to
10ng/mL LAP-TGFβ1 for 18 hours (n=3/cell line +/- LAP-TGFβ1). Serum-starved
MLECs +PAI-1L reported the activation of the exogenously added latent TGFβ.
Wild type transformed astroglia activated significantly more (~30%) LAP-TGFβ1
than the β8-/- transformed cells (Figure 17a). In the samples that were not exposed
to exogenous latent TGFβ, no significant difference among the cell lines was
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observed (Figure 17a, gray bars), suggesting other mechanisms for latent TGFβ
activation.
In vivo analysis was a next logical step to dissect out the 3-D tumor
microenvironment and further evaluate integrin-mediated bioactivation of latent
TGFβs.

Therefore, TGFβ signaling was analyzed by inspecting the nuclear

localization of endothelial phosphorylated Smad-3 (pSmad3), an intracellular
indicator of TGFβRII canonical signaling (125).

β8 integrin tumor-associated

CD31+ vessels exhibited robust pSmad3 nuclear localization (Figure 17b) whereas
knockout tumors, in large part, did not (Figure 17c). Although wild type intratumoral
vessels displayed increased TGFβ activity, a more quantitative assay was
developed to sort out CD31+ endothelial cells from both tumor types. Endothelial
cells isolated from β8 integrin-expressing tumors displayed significantly more
phosphorylated Smad2 (pSmad2) (2-fold) and pSmad3 (3-fold) proteins (Figure
17d; bands were normalized to total-Smad2/3 protein levels).
Collectively, these data suggest that β8-/- astrocytomas pathologies are due
to a defect in αvβ8 integrin-mediated TGFβ bioactivation in the tumor-associated
endothelium.

	
  

79	
  

Figure 16: TGFβ-related Models Examining Paracrine Signaling Biology.
(A) Combined loss of TGFβ1 and 3 (TGFβ1RGE/RGE;TGFβ3-/-) leads to severe
intracerebral hemorrhage (black arrows) absent from wild type littermates (B) (C).
Conditional deletion of TGFβRII on Alk-1 Cre+ endothelial cells mimics integrin
knockout model pathologies, not observed in a control Alk-1 Cre+;flox/+ littermate.
(E) 293-T cells stably transfected (inlayed immunoblot) with human β8 integrin
protein bioactivates latent TGFβs significantly more than non-β8 integrin expressors
(*p<0.05; **p<0.0001). Figure (A-D) adapted from Mu et al. 2008 (110).
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Figure 17: In vitro and in vivo Impaired TGFβ Activation and Signaling in β8-/Astrocytomas.
(A) A PAI-1 luciferase reporter assay shows diminished TGFβ activation in
β8-/- transformed astroglia as compared to wild type transformed astroglia.
Conditioned media (+/- LAP-TGFβ1) from wild type (n=3) or β8-/- (n=3) transformed
astroglia were transferred onto mink lung epithelial cells (MLEC) stably transfected
with PAI-1 luciferase (106) and assayed for luciferase activity shortly thereafter.
Conditioned media from wild type cells pre-treated with LAP-TGFβ1 induced
significantly more luciferase activity as compared to the β8-/- cells (***p=0.04).
Note the significantly reduced luciferase activity of control MLECs never exposed to
TGFβ1 compared to both transformed astroglial cell types - LAP-TGFβ1
(*p<0.0001). Also, note a significant increase of luciferase activity in wild type cells
exposed to TGFβ1 versus control MLECs (**p<0.004). (B) Coronal sections of β8-/astrocytomas stably expressing β8V5 integrin protein and (C) empty vector were
immunofluorescently stained for CD31 (red, vessels) and nuclear pSMAD3 (green)
to monitor canonical TGFβ signaling (400x). Note that most of the β8 expressing
astrocytoma vessels display a nuclearly localized pSMAD3 signal (arrows in B)
whereas non-β8 expressing astrocytomas were largely negative for nuclearly
localized pSMAD3 (arrows in C).

Lower right boxes in B & C are higher

magnifications of boxed areas in 200x images.

(D) CD31+ tumor associated

endothelial cells of β8 expressing astrocytomas exhibited significantly more
pSMAD2 and pSMAD3 protein expression as compared to those non-β8 expressing
astrocytomas (n=3/cell line). β-actin/tSMAD2/3 acted as loading controls.

	
  

81	
  

Figure 17
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Further Evaluation of Wild Type and β8-/- Astrocytomas
Analysis of adhesion and migration characteristics
Using semi-quantitative RT-PCR, wild type and β8-/- transformed astroglia
expressed similar levels of TGFβ1, TGFβ2 and TGFβ3 mRNA (Figure 18a) further
corroborating the necessity of αvβ8 integrin for latent TGFβ activation. Indifferent
ELISA data measuring transformed astroglial TGFβ production into conditioned
media allowed us to disregard the possibility that αvβ8 integrin dictates TGFβ
expression.

Integrins play roles in cellular adhesion and migration, therefore, we

investigated the role of αvβ8 integrin in these processes (15). Furthermore, αvβ3
integrin has been implicated in glioma growth and invasion (99), where it’s often
expressed in GBM tumor cells (87).

αvβ3 and αvβ5 integrins are commonly

overexpressed along the tumor periphery allowing for increased invasion into the
brain parenchyma (97). Therefore, the inherent adhesive nature of wild type and
β8-/- transformed astroglia was evaluated. Both cell lines displayed no obvious
differences in their adhesion or morphological properties (Figure 18b). Next, cells
were plated onto laminin-coated coverslips, and upon reaching confluence, were
scratched and cell invasion was analyzed over 72 hours.

Again, no distinct

differences were observed in their ability to fill in the scratch, suggesting a minimal
in vitro role for αvβ8 integrin during migration (Figure 18c).
Upon evaluation of in vivo characteristics, wild type and β8-/- transformed
cells continued to express robust levels of nestin (Figure 19b) and diminished
amounts of GFAP (Figure 19c). The GFAP signal, observed along the periphery of
the tumors, represents the host’s reactive astrocytes forming a glial scar to
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sequester the tumor from the normal brain parenchyma. A closer look at the tumor
periphery on a representative coronal H&E-stained section of a wild type and β8-/astrocytomas reveals similar patterns of invasion, especially perivascularly (Figure
19a). Taken together, these data do not suggest a role for αvβ8 integrin during
glioma invasion in this orthotopic mouse model of astrocytoma.
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Figure 18: Wild Type and β8-/- Transformed Astroglia Display Similar
Adhesion and Migration Characteristics.
(A) Expression analysis of TGFβ1, TGFβ2 and TGFβ3 mRNAs in wild type
and β8-/- transformed astroglia was determined by semi-quantitative RT-PCR. (B)
Transformed wild type (upper) and β8-/- (lower) astroglia were plated on truncated
LAP peptide-coated coverslips and allowed to adhere for 4 hours.

Cells were

immunofluorescently labeled with phalloidin-Texas Red to visualize the intracellular
actin cytoskeleton. Note no differences in morphological or adhesive properties.
Wild type (C-E) and β8-/- (F-H) transformed astroglia migrated similarly over a 72hour period on laminin coated coverslips.
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Figure 19: Wild Type and β8-/- Astrocytomas Display No Obvious Differences
in Invasiveness in vivo.
(A) Coronal sections from wild type (left panel) and β8-/- (right panel)
astrocytomas were H&E-stained exhibiting the tumor (T) peripheries.

Both

astrocytomas invade into the brain parenchyma similarly. (B) Coronal sections from
wild type (left panel) and β8-/- (right panel) were immunofluorescently stained with
an anti-Nestin antibody exhibiting tangential tumor cell invasion (arrows).

(C)

Coronal sections from wild type (left panel) and β8-/- (right panel) were
immunofluorescently stained with an anti-GFAP antibody revealing non-malignant
reactive astrocytes forming a glial scar along the tumor periphery (arrows).
Conversely, tumors (T) did not express GFAP. (All images=200x)
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Figure 19
	
  

	
  

87	
  

Figure 20: A Model for β8 Integrin-mediated Homeostatic Control of Blood
Vessels in the Normal Brain.
In the normal brain, αvβ8 integrin is expressed on the perivascular astroglia
(blue) allowing for the bio-activation of LAP-TGFβ1 into its bioactive form with the
help of MT1-MMP (49).

Bioactive TGFβ1 targets TGFβRII, which then recruits

TGFβRI leading to intracellular signaling, involved in blood vessel (red)
homeostasis.
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Discussion
Previously, our lab and others have shown that β8 integrin knockout mice
develop severe intracerebral hemorrhage. Although these pathologies have been
well documented (44), little was known about the integrin’s role in brain
tumorigenesis. The data within this chapter is the first to connect the dysregulation
of αvβ8 integrin function to vascular pathologies in high-grade glioma.
Cultured wild type and β8-/- primary astroglia express robust levels of nestin
and GFAP, both markers of putative cells of origin for high-grade gliomas (55).
Oncogenic transformation resulted in a substantial loss of αv and β8 integrin
expression, further supporting a role for αbβ8 integrin in glioma progression.
Although wild type transformed cells were just as tumorigenic as the β8-/- cells in
vivo, the glioma-induced pathologies were far from similar.

Knockout tumors

displayed pathological hallmarks commonly described in grade IV GBMs, namely
intratumoral

vascular

pathologies

including

severe

hemorrhage

inducing

significantly early lethality. Conversely, wild type cells injected into the striatum of
nude mice produced tumors with pathological features consistent with those
observed in grade III anaplastic astrocytomas. Upon forced expression of human
β8 integrin protein in β8-/- transformed astroglia, the majority of vascular
pathologies were largely resolved in vivo. Upon further mechanistic evaluation of
the observed pathologies, impaired TGFβ signaling led to diminished intratumoral
endothelial homeostasis due to absence of αvβ8 integrin on tumor cells. In the
normal resting brain, the perivascular astrocyte expresses robust levels of αvβ8 on
its cell surface. αv integrin subunit binding to the RGD tri-peptide domain in the
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LAP

portion

of

latent

TGFβs

leads

to

the

recruitment

of

MT1-MMP

metalloproteinase by the β8 integrin subunit (49). MT1-MMP is believed to aid in
the physical cleavage of the latent peptide from the inactive cytokine. Upon TGFβ
activation, TGFβ receptors are engaged and intracellular signaling cascades ensue,
functionally contributing to endothelial cell homeostasis (Figure 20). In the disease
state, perivascular αvβ8 integrin expression is diminished, thus deregulating vessel
homeostasis, leading to higher-grade gliomas, as observed in this orthotopic model.
Astrocytes (Figure 7e) and neural progenitor cells (Figure 11d) express
robust levels of αvβ8 integrin, which has recently been established to regulate
neurovascular homeostasis in the adult mouse brain (14).

Furthermore,

homozygous β8 integrin knockout mice display marked increase in intracerebral
blood vessel coverage, suggesting αvβ8 integrin acts as an angiogenic control
switch (49). Indeed, GBM cells play fundamental roles in creating an environment
for increased tumor progression often supported by pathological angiogenesis
(104). With the evidence collected in this first chapter, its strongly believed that
high-grade brain tumor cells downregulate αvβ8 integrin expression and ensuing
function.

As observed in the wild type astroglia, transition from primary to

transformed resulted in a significant reduction in overall αv and β8 integrin
expression (Figure 11b).

Interestingly, significantly higher VEGF-A protein

expression did not lead to increased pathological angiogenesis, as others have
reported (126). Moreover, TGFβ has been characterized as a potent inhibitor of
VEGF and basic fibroblast growth factor (bFGF), both keen contributors to
sustained angiogenesis (127).

	
  

Data presented here further corroborate this

90	
  

phenomena whereby integrin-mediated activation of latent TGFβs functionally
inhibit the pro-angiogenic functions of VEGF highly expressed in the wild type
transformed astroglia as compared to mRNA and protein levels detected in β8-/tumor cells (Figure 15a, b). In addition, TGFβ canonical signaling results in the
phosphorylation of R-Smad3, which as been attributed to enhancing VEGF
expression (128). VEGF production in the β8-/- tumor cells, albeit low, coupled with
impaired TGFβ endothelial cell homeostasis, creates a tumor environment that
promotes pathological angiogenesis resulting in human grade IV GBM-like lesions.
Oncogene-mediated reduction in overall β8 integrin protein expression in
wild type astroglia suggests αvβ8 integrin as a possible tumor suppressor as the
majority of β8-/- astrocytomas resembled pathological hallmarks of human GBM.
On a related note, diminished αvβ8 integrin status alone was not sufficient to induce
spontaneous tumorigenesis, consistent with reports in complete β8 integrin
knockout adult mice (14). Therefore, potential activation of specific oncogenes (i.e.
HRasG12V) coincident with loss of tumor suppressor functions (i.e. pRb/p53) and β8
integrin loss, may lead to spontaneous astrocytomas. Our lab has recently reported
that GFAP-cre conditional knockout of αv integrin in epithelial cells of the eyelid skin
and conjunctiva commonly lead to squamous cell cancer development 12-18
months, post-natally (129). Taken together, loss of integrin expression coupled with
other potent genetic alterations, can lead to tumor formation and progression.
Furthermore, our data revealing loss of β8 integrin expression by passage 8 could
coincide well with p53 loss, a common genetic alteration that occurs early-on during
gliomagenesis, especially in newly forming astrocytomas (130).
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Indeed, these

speculations need to be further investigated to truly understand the dynamic
between αvβ8 integrin function and tumor suppressor/oncogene activities during
gliomagenesis.
The novel concept that αvβ8 integrin is lost during gliomagenesis has
sparked many different avenues of investigation.

The vascular pathologies

observed in the β8-/- astrocytomas were so striking that many of the other integrinrelated functions that could contribute to tumorigenesis were not pursued. Further
analysis of migration and adhesion functions based on αvβ8 integrin expression
status was further elucidated. αv integrins have been identified as being involved in
tumor cell adhesion and migration along white matter tracts and blood vessels
(131).

More specifically, αv integrins have been correlated to promoting colon

cancer liver metastasis. Small molecule inhibitors directed against αvβ3 and αvβ5
integrins reduced overall cell proliferation and adhesion in highly metastatic colon
cancer cells (132). In addition, αvβ3 and αvβ5 integrins are known to play roles in
glioma neo-angiogenesis, but have also been linked to increased expression along
glioma tumor periphery aiding in their migratory capacity into the normal brain
parenchyma (97). Unfortunately for αvβ8 integrin, with regard to this mouse model,
its absence showed no obvious differences in in vitro adhesion and migration
assays (Figure 18b-h), for in vivo peripheral tumor perivascular invasion (Figure
19a, b).

Although these data have identified novel roles for αvβ8 integrin in

pathological angiogenesis in glioma, further focus will be placed upon the role of the
integrin during the human disease setting in the hopes of identifying a new
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therapeutic target to contribute to possible increased prevention and early diagnosis
of GBM.
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CHAPTER 4: Specific Aim 2

Elucidate the Functional Roles for αvβ8 Integrin in Glioma-Induced
Angiogenesis During the Pathogenesis of Human Gliomas

Introduction
In the previous chapter, we utilized a genetically tractable mouse model
whereby β8 integrin was transgenically knocked out, which led to severe
intratumoral hemorrhage (44). Inhibition of p53 and Rb tumor suppressors and
stable incorporation of an oncogenic H-Ras (G12V) into wild type and β8-/- primary
astroglia promoted tumor formation in the striatum of nude mice. Overall, β8-/tumors exhibited significantly increased CD34+ fluorescence intensity partially
attributed to a significant decrease in activation of latent TGFβs. Moreover, mice
harboring knockout transformed astroglia survived significantly less than mice
harboring wild type transformed astroglia. While this orthotopic mouse model of
astrocytoma has revealed a significant role for αvβ8 integrin during gliomagenesis,
further inquiry is necessary to elucidate the functional contributions in human GBM.
Human glioma cell lines harvested from patients have long been
commercially available in order to determine the functional roles of specific genes
and proteins in the disease (133).

Furthermore, freshly resected tumors are a

potential avenue to culture cells and analyze protein expression profiles in different
grades of human glioma. However, one caveat to analyzing bulk tumor masses is
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that they are often infiltrated by stromal reactive astrocytes that have the potential of
skewing expression profiles (134).
In recent years, there has been compelling evidence supporting the presence
of ‘cancer stem cells’ (CSCs) within hematopoietic, breast, colon and brain cancers
(135-138). GBM CSCs are considered to be the primary reason for GBM tumor
recurrence post-therapy due to their ability to remain quiescent while target
therapies target rapidly dividing cells (139). Within the adult human brain, neural
stem cells (NSCs) reside in two specific locations, the subventricular zone of the
lateral ventricle and the subgranular zone of the dentate gyrus of the hippocampus.
NSCs are defined as multipotent cells with the ability to proliferate and self-renew
(140). Upon transformation, primary GBM progenitor cells are identified as a small
subset population (<5%) of the tumor bulk that retain the ability to establish tumors
(141). Recently, our lab and others have begun to culture these CSCs from freshly
resected GBMs. A caveat to this model is that lower grade anaplastic astrocytomas
rarely, if ever, produce CSCs that can be compared to those harvested from GBMs.
Nonetheless, expression and function of αvβ8 integrin will be evaluated.

Next,

primary GBM cell lines will be transduced with lentiviral-based small hairpin RNAs
(shRNAs) to stably silence gene targets including both αv and β8 integrin.
Lastly, a similar genetically tractable mouse model used in the previous
chapter will employ transformed human astrocytes to produce astrocytomas.
Transformed cells were acquired from Dr. Russel Pieper laboratory (80) and
lentiviral-based RNAi technology will ablate β8 integrin expression.

Resulting

intracranial tumors will be characterized based upon their in vivo pathologies in
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order to corroborate the strong body of evidence discussed in the previous chapter.
Collectively, the main objective of this chapter is to elucidate a functional role for
αvβ8 integrin in human gliomas.
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Results
Characterization of αvβ8 Integrin Expression in Human Glioma Cell Lines
A panel of commercially available human GBM cell lines were purchased
(ATCC) or acquired from the Brain Tumor Center at M.D. Anderson and
characterized for αv and β8 integrin expression. Transformed human astrocytes
(THAs) were acquired from Dr. Russel Pieper. Although five of the seven cell lines
evaluated expressed robust levels of αvβ8 integrin, there were two, U87 and LN18,
which expressed little, if any β8 integrin (Figure 21a).

Transformed human

astrocytes lost approximately 90% of β8 integrin expression while also exhibiting a
50% decrease in αv integrin expression (Figure 21a) (142).
To establish a link between β8 integrin expression and in vivo tumor-induced
angiogenesis, U87 and SNB-19 GBM cells were stereotactically injected into the
striatum of immunocompromised mice to evaluate their in vivo tumorigenicity.
500,000 cells were implanted and allowed to form tumors for 6 weeks (n=5 mice/cell
line). The tumor bearing mice were anesthetized and cardiac perfused with 4%
paraformaldehyde.

Macroscopic coronal U87 tumors revealed a hemorrhagic

pathology with tumors forming in nearly the entire injected brain hemisphere (Figure
21b).

H&E-stained tumors contained large, distended vessels that displayed

sinusoidal-like morphologies further confirmed by anti-CD34 immunohistochemistry
(Figure 21d, e). Macroscopic analysis of brains injected with SNB-19 cells did not
exhibit obvious tumor formation (Figure 21c) although microscopic analysis of H&Estained brain sections revealed focal, invasive lesions that preferred growth in a
perivascular manner (Figure 21f). Furthermore, anti-CD34 immunohistochemistry
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showed limited vascular networks with vessels uniform in diameter lacking
hemorrhage, making their vascular patterns distinct from those observed in the U87
tumors (Figure 21g).
In an effort to influence the blood vessel properties in the U87 tumors, a
plasmid expressing human β8 integrin protein was stably transfected into this cell
line.

U87 cells were also stably transfected with empty vector pcDNA4.0.

Expression of β8 integrin was confirmed by western blot analysis (Figure 22a). β8
integrin expressing or empty vector U87 cells were stereotactically injected into the
striatum of immunocompromised mice (n=5 mice/cell line). U87 tumors expressing
β8 integrin lacked the macroscopic hemorrhage (Figure 22b) evident in the U87
empty vector tumors (Figure 22c). Furthermore, a panel of tumors (n=5/tumor) from
both cohorts was immunofluorescently stained with CD34 to label vascular
endothelial cells. U87 vector control tumors exhibited robust microvascular density
(MVD) (Figure 22d) as compared to β8 integrin-expressing U87 tumors (Figure
22e). Upon analysis of CD34 fluorescence, the U87 empty vector fluorescence
intensity was significantly reduced compared to U87 tumors forcibly expressing β8
integrin (Figure 22f).
To assess TGFβ activation and signaling, the two-cell approach was
employed comparing β8 integrin low expressing GBM cells versus those that
express high levels. In addition to the U87 and SNB-19 cell lines, LN18 and LN229
lines were also analyzed as these express low and high levels of αvβ8 integrin,
respectively. As depicted in Figure 23, those cell lines (LN229 and SNB-19) that
express high levels of αvβ8 integrin activated significantly more latent TGFβ1
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compared to those low expressers (LN18 and U87) (Figure 23, black bars).
Moreover, endogenously produced latent TGFβs are also significantly activated
more in high expressing cell lines versus U87 cells (Figure 23, gray bars).
Collectively, these data suggested that the gross hemorrhagic and
microscopic vessel pathologies observed in the U87 tumors are, in part, due to a
defect in integrin-mediated activation of latent TGFβs upon the tumor-associated
vasculature. Indeed, forced expression of β8 integrin in tumor cells diminished
these pathologies, therefore providing further evidence that αvβ8 integrin plays
significant roles in regulating intratumoral angiogenesis.
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Figure 21: αvβ8 integrin Expression in Human Glioma Cell Lines
(A) Normal and transformed human astrocytes (NHA/THA) and seven human
glioma cell lines were immunoblotted with antibodies directed against αv integrin, β8
integrin and actin proteins. Note the diminished loss of β8 integrin expression in
THAs upon transformation, similar to wild type mouse transformed astroglia. Also,
notice that some cell lines express differential levels of β8 integrin. U87 glioma
cells were intracranially injected into the striatum of nude mice (n=5) and cardiac
perfused upon tumor formation. Gross coronal sections (B) were stained with H&E
(D, 100x) and an anti-CD34 antibody (E, boxed area, 400x). Notice that U87 cells
form large intracranial tumors with evidence of vascular hemorrhage and sinusoidallike vessels (red arrows). SNB-19 glioma cells were intracranially injected into the
striatum of nude mice (n=5) and cardiac perfused upon tumor formation. Gross
coronal sections (C) were stained with H&E (F, 100x) and an anti-CD34 antibody
(G, boxed area, 400x). Note the relatively low vascularity of the tumors (red arrows)
compared to U87 tumors and their desire to proliferate periventricularly.
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Figure 22:

Forced Expression of β8 Integrin in U87 Glioma Cells Largely

Resolves Macroscopic Vascular Pathologies.
(A) Stably transfected U87 cells (empty vector and vector+β8-V5) were lysed
and immunoblotted with antibodies against β8 integrin and actin.

Note the

substantial increase in β8 integrin expression. (B) Both cell lines were
stereotactically injected into the striatum of immunocompromised mice (n=5/ cell
line).

The brains were coronally sectioned; notice the intratumoral hemorrhage

evident in the empty vector tumors (pcDNA4.0) (C) is completely resolved upon
forced expression of β8 integrin protein. (D) U87 glioma tumors stably transfected
with an empty (D) or a human β8 integrin-expressing vector (E) were
immunostained with an anti-CD34 antibody to visualize vascular endothelial cells
(Images: 200x). Note the (arrows in D) higher microvascular density in the empty
vector expressing tumors versus the relatively minimal vascularity observed in the
rescue U87 tumors (arrows in E). (F) Fluorescence was imaged and quantified to
exhibit a significant rescue of microvascular density in the U87 tumors forcibly
expressing β8 integrin protein (*p<0.0001).
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Figure 22
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Figure 23: Impaired TGFβ Activation in Human Glioma Cell Lines
A PAI-1 luciferase reporter assay shows substantial reduction of TGFβ
activation in glioma cell lines that express minimal β8 integrin expression versus
those that expressed elevated levels. Conditioned media (+/- LAP-TGFβ1) from
LN18 (n=3), LN229 (n=3), U87 (n=3), or SNB-19 (n=3) were transferred onto
MLECs stably transfected with PAI-1 luciferase and assayed for luciferase activity
shortly thereafter. First, endogenous latent TGFβs (gray bars) activated by U87
cells were significantly less activated than LN229 and SNB-19 cells (*p<0.02 (U87
v. LN229); **p<0.001 (U87 v. SNB-19)). Second, exogenously added latent TGFβs
to LN229 cells led to significantly higher luciferase activity as compared to U87 cells
(++p<0.0001) and LN18 cells (##p<0.01). Lastly, exogenously added latent TGFβs
to SNB-19 cells led to significantly higher TGFβ activity as compared to U87 cells
(***p<0.0001) and LN18 cells (+p<0.03).
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Characterization of αvβ8 Integrin Expression in Human Glioma Samples and
Primary GBM Cell Lines
Dr. Frederick Lang of MD Anderson Cancer Center kindly supplied us with
freshly resected human glioma samples. Lysates made from 8 GBM samples, 3
anaplastic

astrocytomas,

1

ependymoma

and

1

oligodendroglioma

were

immunoblotted to characterize their respective αvβ8 integrin expression (Figure
24a). Upon normalization to actin loading control bands, there seemed to be a
slight trend towards decreased expression in the GBM samples as compared to the
anaplastic astrocytomas, although this difference was not statistically significant.
Consistent with reports showing infiltrative reactive astrocytes along the tumor
periphery and intratumorally (134), these αvβ8 integrin expressing stromal cells may
have skewed our expression profiling. Furthermore, upon effective tumor resection,
a surgeon will always have margins that contain normal, non-neoplastic tissue that
again could affect expression analysis. Indeed, expression may be present within
these tumors, although there may exist a more spatial expression pattern such as
perivascularly.
Our lab and others have cultured primary GBM cell lines, which grow as
neurospheres in a serum-free, growth factor-supplemented media (Figure 24b, top).
These spheroids express robust levels of nestin (Figure 24b, bottom), an
intermediate filament protein and an established marker for neural stem cells (138).
Within a population of primary GBM cell lines, there are distinct expression patterns
evident by FACS analysis. CD133, a marker for cancer stem cells, including those
in GBMs (143), is differentially expressed among the primary GBM cell lines.
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Approximately 50% of the single cells that make up the neurosphere express high
levels of CD133. In another primary GBM cell line analyzed, only 8% of the cells
expressed the cell surface marker, consistent with reports of varying expression
within these primary brain tumor cells (144), as well as in melanoma and pancreatic
cancer (145).

Unfortunately, CD133 expression does not correlate with

tumorigenesis as CD133- populations produce intracranial tumors, making
necessary the discovery of additional biomarkers (146). Several labs have further
characterized these primary cells for different markers under normoxic and hypoxic
conditions. During times of oxygen deprivation, HIF1α is upregulated to initiate a
significant spike in IL-8 secretion, a powerful angiogenic chemokine (147).
Moreover, concomitant activation of Akt and Ras proteins in neural progenitors has
produced intracranial lesions, similar to grade IV GBMs (65).
Due to the lack of specific anti-β8 integrin antibodies for FACS, we used an
anti-αv antibody to elucidate the expression profile of the CD133+ spheroids. Of
this population, 27% of the cells expressed high levels of αv integrin and 20%
expressed low levels (Figure 24c). Next, a panel of four primary GBM cell lines,
NSC-2, -11, -23 and HT18, were biotinylated and exhibited robust expression levels
of αvβ8 integrin (Figure 24d). Although previous data would suggest that these
GBM cells would express low levels of the integrin, these cells are progenitor-like
compared to those examined in the orthotopic mouse and xenograft (human glioma
cell lines) models and therefore may have different integrin expression patterns.
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Figure 24:

Human Glioma and Primary GBM Cells αvβ8 Integrin

Characterization
(A) Freshly resected human glioma tumor samples were lysed and
immunoblotted with antibodies against β8 integrin (upper panel), αv integrin (middle
panel) and actin (lower panel) proteins.

(Key: CB=Normal cerebellum;

O=Oligodendroglioma;

AA=Anaplastic

E=Ependymoma;

Astrocytoma;

GS=Gliosarcoma; GBM=Glioblastoma multiforme). Primary GBM cells grew in a
manner similar to neurospheres, in suspension (B, top image).

A GBM

neurosphere was immunostained with anti-Nestin and anti-DAPI (nuclear stain)
antibodies (B, bottom panel) (Images: 200x). (C) FACS analysis of NSC11 displays
four different populations of cells: Q1: CD133+/αvLO; Q2: CD133+/αvHI; Q3: CD133/αvLO; Q4: CD133-/αvHI. 27% of the NSC11s expressed high levels of CD133 and αv
integrin while 20% expressed low levels of αv integrin (CD133+). This data reveals
distinct populations within the primary GBM cell lines. (D) Primary GBM cell lines
cultured from tumor resections were grown in specialized media.

Cell-surface

analysis of integrin expression on NSC2, 11, 23 and HT18 revealed similar levels of
αvβ8 integrin.
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Figure 24
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shRNA-mediated silencing β8 Integrin Expression in Primary GBM Cells
Next, β8 integrin gene expression was stably silenced via an shRNA
lentiviral-based system whereby primary GBM cells were transduced with β8shRNA
or non-targeting (NT) shRNA coupled to green fluorescent protein (GFP) expression
(107). NTshRNAs were used to identify incorporation of the lentiviral construct via
GFP fluorescence, although the sequence was completely non-specific.

Upon

successful transduction, retroviral-positive cells were marked green and sorted via
live-cell flow cytometry (Figure 25b). After allowing 24 hours for the cells to recover
after sorting, lysates were prepared to evaluate β8 integrin expression. In three of
the four primary GBM cell lines transduced with β8shRNA, substantial knockdown
was achieved, most potently in the NSC-2 and NSC-11 populations (Figure 25a).
500,000 cells (NSC-2, -11, HT18) were stereotactically injected into the striatum of
immunocompromised mice. Indications of tumor burden were evident by 5 weeks
for NSC-2 and NSC-11 lines versus 8 weeks for the HT18 line (n=8/cell line). Upon
macro- and microscopic analyses of these tumors, limited phenotypic differences
were observed (Figure 26). There are various reasons for the lack of differences in
tumor growth and angiogenesis. First, β8 integrin knockdown was substantial,
although, similar levels of β8 integrin expression were observed in wild type
transformed astroglia, which produced tumors that were pathologically less severe
than β8-/- tumors. Thus residual β8 integrin expression in primary GBM cell lines
may be sufficient to negate the formation of tumors exhibiting previously described
severe intratumoral pathologies. Second, increased expression of other αv integrins
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could be compensating for the loss of the β8 subunit, thereby reducing the
anticipated presence of pathological differences.
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Figure 25: shRNA-mediated Stable Silencing of β8 Integrin
(A) Four primary GBM cell lines were stably transduced with non-targeting
(NT)-shRNA or β8shRNA. Lysates were immunoblotted with antibodies against β8
integrin and actin. Note the substantial knockdown of β8 integrin in 3 of the 4
primary GBM cell lines. (B) Brightfield and GFP images of representative NTshRNA
and β8shRNA primary GBM cell lines (NSC-11, images: 100x). Note the intense
GFP signal in both cohorts.
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Figure 26: Microscopic Views of NT- and β8shRNA Intracranial Tumors
Three different primary GBM cell lines stably transduced with NTshRNA or
β8shRNA lentiviruses were stereotactically implanted into the striatum of
immunocompromised mice (n=8 mice/cell line). (A) NSC-2, (B) NSC-11 and (C)
HT-18 coronal sections were stained with H&E (images 100x). Note the minimal
differences in tumor phenotype upon knockdown of β8 integrin protein.
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shRNA-mediated silencing αv Integrin Expression in Primary GBM Cells
A lentiviral shRNA was developed to silence αv integrin expression to
address the possibility of compensation or functional redundancy by other integrins
in the β8 integrin knockdown tumors. NTshRNA and αvshRNA lentiviruses were
transduced into NSC-2, -11, -23 and HT18 primary GBM cell lines (Figure 27a).
Upon transduction, GFP-positive cells were sorted and allowed to recover for
several days post-sort (Figure 27b). The primary GBM cell lines were lysed and
immunoblotted with an anti-αv integrin antibody. Substantial knockdown of 80% or
more was established in all four primary GBM cell lines (Figure 27a), although β8
integrin expression did not change (data not shown). 500,000 cells (NSC-2 and
NSC-11) were stereotactically injected into the striatum of immunocompromised
mice and signs of tumor burden were obvious after 5 weeks (n=6 mice/cell line).
Similar to β8shRNA tumors, macro- and microscopic evaluation of NSC-2
NTshRNA and αvshRNA tumors revealed limited phenotypic differences (Figure
28a-d).

Furthermore, pathological differences among NSC-11 NTshRNA and

αvshRNA tumors were not obvious (Figure 28e-h), although there was evidence of
macroscopic hemorrhage in three of the eight animals injected (Figure 28f).
These data suggest that compensation or functional redundancy may not be
the reason for a lack of pathologies in the β8shRNA tumors.

There are other

possible reasons as to why differences are not observed. Within the population of
the knockdown cells, there are most likely subpopulations that may express high
levels of αvβ8 integrin.

This subpopulation may dominate in vivo and the

subpopulation with diminished integrin expression may proliferate at a slower rate.
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Secondly, existing mutations may also prove αvβ8 integrin expression status
negligible as more potent oncogenes may overshadow the integrin’s role in vivo.
Lastly, the integrin may be mutated as well.
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Figure 27: shRNA-mediated Stable Silencing of αv Integrin
(A) Four primary GBM cell lines were stably transduced with non-targeting
(NT)-shRNA or αvshRNA. Lysates were immunoblotted with antibodies against αv
integrin and actin. Note the substantial knockdown of αv integrin in all 4 primary
GBM cell lines. (B) Brightfield and GFP images for a representative NTshRNA and
αvshRNA primary GBM cell lines (NSC-11, images: 100x). Note the intense GFP
signal in both cohorts.
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Figure 28:

Micro- and Macroscopic Images of non-targeting (NT)- and

αvshRNA Intracranial Tumors
Two of the four different primary GBM cell lines that were stably transduced
with NTshRNA or αvshRNA lentiviruses were stereotactically implanted into the
striatum of immunocompromised mice (n=8 mice/cell line). (A) NSC-2 NTshRNA
and (C) αvshRNA tumors were coronally sectioned. No obvious macroscopic and
microscopic differences in tumor phenotypes (images: 200x) were detected via H&E
staining (B, D). (E) NSC-11 NTshRNA and (F) αvshRNA tumors were coronally
sectioned. Note the hemorrhagic phenotype (3 of 8 mice injected) in the αv integrin
knockdown tumors from a macroscopic standpoint (F).
hemorrhage were detected in NTshRNA tumors.

Punctate patterns of

H&E-stained coronal sections

showed minimal microscopic differences with the tumors (200x).
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Figure 28
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Sorting αvHI and αvLO NSC-2 and NSC-11 Primary GBM Cells
To evaluate the role of αvβ8 integrin expression utilizing primary GBM cells,
NSC-2 and NSC-11 cells were stained with an anti-αv integrin antibody. The top
and bottom 15% of these populations, in terms of αv integrin expression, were
isolated and termed αvHI and αvLO (Figure 29a, b). Sorting efficiency was verified
via immunoblotting the populations for αv integrin protein (Figure 29c). Surprisingly,
β8 integrin expression did not change among the sub-populations. Next, 200,000
freshly sorted NSC-2 and -11 αvHI and αvLO primary GBM cell lines were injected
into the striatum of immunocompromised mice (n=5 mice/sorted population) and
neurological signs of tumor formation were evident with 5 weeks. Macroscopically,
NSC-2 and NSC-11 αvLO tumors displayed only minimal evidence of hemorrhage, at
best, although overall tumor size was strikingly different from NSC-2 and NSC-11
αvHI tumors (Figure 30a-d, left panel).

H&E staining of tumors revealed no

differences in microscopic phenotype, although differences in tumor volumes were
quite obvious (Figure 30a-d, right panel). Resulting αvLO tumors were significantly
larger than avHI tumors in both primary GBM cell lines (Figure 30e). Therefore,
sorting of ‘true’ αvβ8 high and low expressing populations could prove beneficial in
divulging the role of the integrin in the human disease using the primary GBM cell
model.
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Figure 29: FACS of αvHI- and αvLO-expressing Populations
(A) NSC-2 and (B) NSC-11 primary GBM cells were sorted for αv integrin
high and low expressing populations. Top and bottom 15% of each population was
isolated

and

stereotactically

injected

directly

into

the

striatum

of

immunocompromised mice (n=5/population). (C) All four populations were lysed to
verify high and low expression profiles anti-αv and β8 integrin and actin antibodies.
Note the substantial decrease in αv integrin expression in the αvLO lanes.
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Figure 30: Intracranial Injection of NSC-2 and NSC-11 αvHI and αvLO
Populations
Sorted populations (αvLO and αvHI) for NSC-2 (A, B) and NSC-11 (C, D) were
stereotactically injected into the striatum of immunocompromised mice. Animals
were cardiac perfused and coronally sectioned.

H&E-stained sections reveal

substantial tumor size differences. (E) Macroscopically, αvLO tumors were
significantly larger than αvHI tumors in both NSC-2 (*p<0.01) and NSC-11 (**p<0.02)
tumor bearing animals as assessed by quantitating tumor volumes (n=5).
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Figure 30
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Evaluation of αvβ8 Integrin Functions in Transformed Human Astrocytes
Pieper and colleagues developed a model to analyze the roles of astrocytederived gliomas by genetically modifying normal human astrocytes (NHAs) (148).
First, they showed that retroviral transduction of NHAs with human telomerase
catalytic component (hTERT) and E6/E7 oncoproteins allowed the cells to surpass
cellular senescence but did not induce transformation. Only upon transduction with
mutant H-Ras (G12V), enhancing MAPK signaling cascades and mimicking EGF
receptor hyperactivation, did transformation occur (80).

Pieper and colleagues

concluded that the triple retroviral transduction of normal human astrocytes leads to
the formation of grade III anaplastic astrocytomas upon implantation into the
cerebral cortex of immunocompromised mice (80). Our lab confirmed this result
with immortalized primary mouse astroglia, which were unable to form intracranial
tumors (data not shown).

However, upon delivering mutant H-Ras (G12V),

transformed mouse astroglia were able to proliferate in a growth anchorage
independent manner as well as form robust intracranial lesions.
This human cell system was used to model astrocytomas to evaluate the role
of αvβ8 integrin and determine if lentiviral knockdown of β8 integrin increases tumor
severity, similarly observed in the mouse model data in chapter 3. Similar to wild
type mouse astroglia, transformation of NHAs reduced β8 integrin expression by
nearly 90% (Figures 11b/21a). Transformed human astrocytes (THAs) were stably
transduced with NTshRNA and β8shRNA lentiviruses. Transduced cell populations
show robust levels of GFP indicating a high level of transduction efficiency (Figure
31a, bottom panel). GFP positive populations were sorted and knockdown was
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verified via immunoblotting with anti-αv and -β8 integrin antibodies. Gene silencing
was nearly 100% complete whereby limited expression was seen in the THAs +
β8shRNA (Figure 31b).
A variety of in vitro studies were performed on these manipulated cell
populations analyzing cell proliferation, colony formation and migration via wound
healing and matrigel invasion assays. 25,000 NTshRNA and β8shRNA THAs were
plated (n=3/cell line/timepoint) and cells were counted every 24 hours thereafter for
4 days. NTshRNA THAs proliferated significantly faster at 48, 72 and 96 hours after
plating (Figure 31c).

Conversely, β8shRNA THAs produced significantly more

colonies in a soft agar colony formation assay compared to NTshRNA THAs
(n=3/cell line) (Figure 31d). NTshRNA and β8shRNA THAs were plated on glass
coverslips and allowed to grow to confluence (n=3/cell line). Cell-free regions were
generated using a P-10 pipette tip and imaged over 36 hours via a live-cell imager.
β8shRNA THAs took significantly longer to close the wound than NTshRNA THAs
(Figure 31e).

Furthermore, a matrigel invasion assay further supported this

evidence. 50,000 NTshRNA and β8shRNA THAs were plated on the upper side of
the matrigel invasion insert while using 10% FBS as a chemoattractant to initiate
cell migration. Invasion was quantified by measuring crystal violet absorbance of
contralaterally migrated cells.

β8shRNA THAs invaded significantly less than

NTshRNA THAs (Figure 31f).
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Figure 31: β8 Integrin Stable Knockdown of Transformed Human Astrocytes
Transformed human astrocytes (THAs) were stably transduced with
NTshRNA (A, left panel) and β8shRNA (A, right panel) lentiviruses and GFP+ cells
were sorted. (Images=100x)

(B) Lysates were immunoblotted with rabbit

polyclonal antibodies directed against β8 integrin, αv integrin and actin. Note the
substantial knockdown of β8 integrin protein (left lane). (C) Transformed human
astrocytes (THAs) transduced with β8shRNA showed significantly reduced cell
proliferation as compared to the NTshRNA cells (n=3/timepoint) (48h.*p<0.001;
72h.*p<0.001; 96h.*p<0.002).

(D) β8shRNA THAs formed significantly more

colonies in a soft agar assay compared to NTshRNA THAs (n=3/cell line) (*p<0.04).
(E) In time-lapse videos, β8shRNA THAs required significantly more time to close
the wound as compared to NTshRNA THAs (n=3/cell line) (*p<0.04). (F) In a
matrigel invasion assay, β8shRNA THAs migrated at a significantly reduced rate as
compared to NTshRNA THAs (n=3/cell line) (*p<0.01).
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Figure 31
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250,000 NTshRNA and β8shRNA THAs were stereotactically injected in the
striatum of immunocompromised mice (n=5/cell line). Five weeks after injection,
mice developed clear signs of tumor burden including severe weight loss, hunched
posture and in nearly all β8shRNA tumor bearing mice, severe hydrocephaly.
Macroscopically, β8shRNA coronally sectioned tumors exhibited extremely large,
hemorrhagic, non-invasive tumors on the ipsilateral side of injection (Figure 32b)
whereas NTshRNA tumors were considerably smaller although they showed
evidence of punctate hemorrhage (Figure 32a). After H&E staining, tumor volumes
were quantified. β8shRNA tumors were significantly larger than NTshRNA tumors
(Figure 32c), consistent with the higher colony formation rate of β8shRNA THAs in
vitro. Representative coronal tumor sections were also H&E-stained to reveal a
well-vascularized NTshRNA tumor. In addition, intratumoral vessels were lined with
laminin and expressed CD31, an endothelial cell marker (Figure 33a). β8shRNA
coronal H&E-stained tumors revealed an increase in vessel size and overall density
with areas of obvious hemorrhage.

Further analysis of intratumoral vessels

revealed substantial differences in vessel architecture within tumors (Figure 33b).
For example, β8shRNA tumors revealed significantly more microvascular density
compared the NTshRNA tumors (Figure 33c). Although knockdown tumors were
much larger and vascularized than control tumors, their tumor peripheries were noninvasive, as evidenced by GFP tumor cell fluorescence (Figure 33b, lower panel).
NTshRNA tumors had clear areas of invasive fronts at the tumor periphery (Figure
33a, lower panel). Moreover, GFP+ tumor cells were detected several microns
away from the tumor bulk (data not shown).
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Figure 32:

Intracranial Injections of NTshRNA and β8shRNA Transformed

Human Astrocytes
Immunocompromised mice were stereotactically injected with NTshRNA
(n=8) and β8shRNA (n=8) transformed human astrocytes.

Gross macroscopic

coronal sections of NTshRNA (A) and β8shRNA (B) tumors reveal a robust
difference in both tumor size and hemorrhagic phenotypes (arrows). (C) Tumor
volume was quantified exhibiting β8shRNA tumors were significantly larger than
NTshRNA tumors (n=5) (*p<0.001).
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Figure 32
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Figure 33: Histological Analysis of NTshRNA and β8shRNA THA tumors
Coronal sections of NTshRNA (A, top panel) and β8shRNA (B, top panel)
tumors were stained with hematoxylin and eosin (H&E) and visualized
microscopically (200x).

Note the increase in vessel size in knockdown tumors.

Coronal sections of NTshRNA (A, middle panel) and β8shRNA (B, middle panel)
tumors were doubly immunostained with an antibody against the vascular basement
membrane (arrows), laminin (red) and an anti-nuclear stain, DAPI (blue) (400x).
Note the significant increase in vessel size and volume in the knockdown tumors.
Confocal microscopy on coronal frozen sections of NTshRNA (A, bottom panel) and
β8shRNA (B, bottom panel) tumors were stained with an antibody against the green
fluorescent protein (GFP; green) expressed on tumor cells and against vascular
endothelial cells (CD31; red) (400x).

Note the well-defined and non-invasive

β8shRNA tumor periphery (arrow) as compared to the migratory cells at the
NTshRNA tumor margins (arrows).

(C) CD34 fluorescence, another marker of

vascular endothelial cells, was measured to exhibit the significant increase in
microvascular density in β8shRNA tumors versus NTshRNA tumors (n=5/tumor)
(*p<0.001).
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Elucidating the Mechanism Behind the β8shRNA Tumor Pathologies
Similar to the data for VEGF protein levels in conditioned media from wild
type and β8-/- transformed mouse astroglia, nearly identical results were found in
conditioned media from NTshRNA and β8shRNA THAs. Both THAs lines were
plated (n=3) and allowed to grow and condition media for 48 hours after which a
human-specific ELISA was used to measure VEGF-A production. NTshRNA THAs
produced significantly more VEGF than β8shRNA THAs, in vitro (Figure 34a).
Substantial increase in VEGF production would most likely drive tumorigenesis and
increase the severity of the tumor, although Sonoda et al. showed the exact
opposite. THAs that are forced to overexpress VEGF did not convert grade III
anaplastic astrocytomas to GBM (120). Perhaps, the loss of αvβ8 integrin leads to
tumor progression to grade IV, suggested by the differences in blood vessel
characteristics among the β8shRNA lentiviral-infected THAs.
Next, a TGFβ activation assay was performed on the NT- and β8shRNA
THAs.

Cells were transiently transfected with the truncated PAI-1L promoter

plasmid (106). Next, both cell lines were exposed to 10ng/ml LAP-TGFβ1 for 18
hours.

The following day, cells were lysed and firefly luciferase activity was

assessed.

There was significantly less TGFβ activation in the β8shRNA THAs

versus the NTshRNA THAs (Figure 34b, black bars). Furthermore, endogenously
produced latent TGFβs produced by the THAs was unable to be activated in those
cells stably transduced with the β8shRNA lentivirus (Figure 34b, gray bars). Taken
together, these data further suggest a role for αvβ8 integrin-mediated activation of
latent TGFβs, similarly observed in the orthotopic mouse model.
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Lastly, a Kaplan-Meier survival study was initiated to determine if the
β8shRNA tumors would cause early lethality.

50,000 cells (NT- and β8shRNA

THAs) were stereotactically injected in the striatum of immunocompromised mice
(n=7 mice/cell line). Tumors were allowed to grow until the mice succumbed to
tumor burden. β8shRNA tumor bearing animals survived significantly less than
NTshRNA tumor bearing animals (Figure 34c). Increased time to lethality in the
knockdown tumor bearing mice was likely due to the severe hydrocephaly and
enhanced tumor size.
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Figure 34:

Mechanism and Survival Analyses of NTshRNA and β8shRNA

Tumors.
(A) NTshRNA transformed human astrocytes condition media contained
significantly more VEGF than β8shRNA transformed human astrocytes, as
assessed by ELISA (n=3/cell line) (*p<0.001).

(B) NTshRNA and β8shRNA

transformed human astrocytes were transiently transfected with the PAI1-L vector to
measure TGFβ activity. Conditioned media from NTshRNA cells, pre-treated with
LAP-TGFβ1, induced significantly more luciferase activity as compared to β8shRNA
cells (n=3/cell line) (*p<0.001).

(C) Kaplan Meier survival analysis reveals a

significant overall reduction in survival in β8shRNA tumor bearing mice (n=7) versus
NTshRNA tumor bearing mice (n=7) (*p<0.04 at 50% survival).
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Figure 35: A Model for αvβ8 Integrin-mediated Regulation of Tumorigenesis in
the Brain.
(A) Perivascular astrocytes expressing αvβ8 regulate cerebral blood vessel
growth and stability by adhesion to ECM proteins, i.e. latent TGFβs. (B) Upon cell
transformation, αvβ8 integrin expression is down-regulated, thus ‘priming’ cells to
exploit the vascular niche to promote tumor growth and survival. (C) As lower grade
astrocytomas acquire more genetic mutations, these tumors progress to GBM
status while αvβ8 integrin expression and function is lost in the perivascular tumor
niche, thus promoting angiogenesis pathologies commonly identified in GBM.
Decreased tumor cell invasion and robust tumor growth are also evident.
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Discussion
In this chapter, we extended our studies of αvβ8 integrin in mouse gliomas to
human gliomas. A previous report has documented increased of β8 integrin mRNA
expression in human GBM samples (103), although their focus was on primary de
novo GBMs as oppose to secondary GBMs, which resemble the mouse model
described in the previous chapter. In addition, they analyzed bulk tumor masses
rather than distinct tumor cells, as they harbor stromal infiltrative reactive astrocytes
that may serve as a false positive. Secondly, our lab has concluded that the ‘β8specific’ antibody used in these studies lacks specificity, as complete β8-/- mouse
brains show similar staining patterns to wild type mouse brains. Furthermore, their
non-malignant brain tissue used to compare with human GBMs was cultured from
cerebral cortices rather than neurogenic regions of the brain, such as the
subventricular zone, which harbor neural stem cells, which are putative cells of
origin for GBMs (84, 149).
This aim has revealed a significant role for αvβ8 integrin in human gliomas
beginning with the evaluation of expression in adherent cell lines.

Although a

majority of the samples expressed the integrin, the ones that did not exhibited
robust intratumoral hemorrhage and other vascular pathologies (Figure 21b, 22c)
that were largely resolved upon forced expression of β8 integrin protein (Figure
22b). In addition, microvascular density and vessel size were largely reduced in
those β8 integrin expressing U87 tumors (Figure 22f). Interestingly, the U87+β8V5
tumor cells produced significantly more VEGF into the conditioned media compared
to empty vector U87 cells (data not shown), similarly observed in wild type
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transformed mouse astroglia. Further mechanistic investigation confirmed the role
of αvβ8 integrin in endothelial cell growth control based upon the significantly
reduced bioactivation of latent TGFβs in low β8 integrin expressing tumor cells
(Figure 23).
Evaluation of αvβ8 integrin expression in freshly resected human glioma
samples revealed limited differences in total β8 integrin expression levels (Figure
24a).

However, these data are likely skewed by the stromal infiltrates, e.g.

astrocytes, and non-malignant brain tissue present in the tumor specimens.
Resected GBM samples gave us ample opportunity to culture primary cells in order
to study the integrin’s role in glioma progression.

However, upon successful

knockdown of αv and β8 integrin subunits using lentiviral-delivered shRNAs,
differences in tumor phenotypes were not obvious (Figure 26, 28). Although limited
pathological differences were observed, it was most likely not due to alternate
integrin compensation following β8 integrin knockdown. Subpopulations of cells still
expressing the integrin may be the primary cause for a lack of pathologies in the αv
and β8 integrin knockdown primary GBM cell line tumors.

Perhaps, spatial

patterning of those cells have a tendency to grow in a perivascular manner, similarly
seen by neural stem cells in the vascular niche (150). Furthermore, the residual
αvβ8 integrin expression after lentiviral knockdown may not be sufficient to generate
a difference in pathological outcomes and these cells may populate the tumor at a
faster rate than the knockdown cells. In addition, the primary GBM cell lines used in
this study could have more potent oncogenic potential that may mask presence or
absence of αvβ8 integrin expression, in vivo. Lastly, upon sorting αv integrin low
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and high expressing sub-populations, the most convincing results towards our
understanding of the integrin’s role in the human disease with regard to the primary
GBM cell line tumor model, became evident. A significant increase in tumor volume
was revealed in those tumors expressing low levels of αv integrin, suggesting a
suppressive role for this integrin in tumor progression. Although the angiogenic
profiles of the αv integrin low tumors were no different than the αv integrin high
tumors, many tumor cells have been known to upregulate integrins that are protumorigenic while down regulating ones that are growth inhibitory (151).
Furthermore, αv integrin’s presence may have an autocrine role in growth inhibition
upon the activation of latent TGFβs leading to the expression of CDK inhibitors and
perturbing cell cycle progression (152). In addition, upon successful sorting of high
and low αv integrin expressing sub-populations, β8 integrin proteins levels remained
unchanged (Figure 29c). The αv subunit is responsible for the binding of the RGD
tri-peptide domain in latent TGFβs, therefore αv integrin low expressing tumors
could exhibit TGFβ growth inhibition, but the residual αv integrin expression,
coupled with unchanged β8 integrin expression, may inhibit expected vascular
pathologies.
In a more genetically tractable model, normal human astrocytes were
transformed and these formed intracranial lesions, indicative of grade III anaplastic
astrocytomas (80). Utilizing this model provided us with better control of the genetic
modifications to the cell line being studied. Surprisingly, lentiviral RNAi technology
targeting of β8 integrin resulted in nearly 100% knockdown (Figure 31b).
Furthermore, stereotactic intracranial tumors formed significantly larger, and
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strikingly, more hemorrhagic tumors than control tumors (Figure 32a, b). These
pathologies led to a significant decrease in overall survival, which correlated with
impaired TGFβ activation and signaling in endothelial cells. In this model, the near
complete silencing of β8 integrin expression led to the significant decrease in
autocrine TGFβ signaling, which would suggest a pro-proliferative environment,
even though αv integrin expression remained unchanged.

Resulting vascular

pathologies resembled those found in the mouse model discussed in Chapter 3,
whereby impaired paracrine TGFβ activation was determined to be a possible
mechanism. In this model, the same idea would hold true. Collectively, defective
TGFβ activation would reduce growth inhibition and promote angiogenesis as
evidenced in the silenced THA tumors.
Another significant finding in the THA mouse model was the substantial
decrease in migration and invasion upon β8 integrin gene silencing. Wound healing
and matrigel invasion assays provided data that were very obvious in vitro.
Silenced tumors grew in a similar manner to U87 parental tumors exhibiting large
lesions with non-invasive margins. Bello and colleagues have described αvβ3 and
αvβ5 integrins as being prominent proteins expressed on the tumor periphery
responsible for migration and invasion (97); therefore, αvβ8 integrin could have the
same effect in this model, as the data would suggest. Furthermore, control tumor
cells invade and migrate faster, which carries over to the in vivo setting. Stimulation
of adherent glioma cell lines with TGFβ has promoted migration (153), which could
be a result of αvβ8 integrin expression and therefore explain the non-invasive
tendencies of the silenced tumors.
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Collectively, these data identify an important role for αvβ8 integrin in human
gliomagenesis.

Vascular and invasive pathologies highlight those processes

regulated by αvβ8 integrin in this chapter. In the normal brain, αvβ8 integrin acts in
concert with TGFβ activation homeostatically regulating the cerebral blood
vasculature.

Upon accumulation of somatic mutations, αvβ8 integrin is down-

regulated setting up the vascular niche for aggressive tumor growth and survival.
As lower grade astrocytomas gain additional genetic mutations, αvβ8 integrin
expression is lost promoting robust angiogenesis and tumor growth commonly
observed in GBM (Figure 35).
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Summary
This investigation is the first to link αvβ8 integrin to pathologies associated
with astrocytomas, particularly GBM. Several key observations were made and are
detailed below:
1.

Wild type transformed astroglia formed intracranial tumors that were
indicative of grade III anaplastic astrocytomas, whereas β8-/- transformed
astroglia gave rise to tumors that were more similar to grade IV GBMs.

2.

β8-/- mouse tumors exhibited hemorrhagic pathologies and enhanced
vascular density that resulted in premature lethality.

3.

Forced β8 integrin protein expression in β8-/- transformed astroglia
largely resolved in vivo vascular pathologies in β8-/- mouse tumors.

4.

β8-/- tumor pathologies were due, in part, to impaired integrin-mediated
TGFβ activation and signaling in blood vessels.

5.

U87 human glioma cell lines, expressing low levels of β8 integrin,
recapitulated β8-/- mouse tumor pathologies and were resolved upon
forced expression of β8 integrin protein.

6.

Primary GBM αvLO cells produced significantly larger tumors than αvHI
cells.

7.

Stable lentiviral silencing of β8 integrin protein in transformed human
astrocytes (THAs) resulted in significantly larger and more hemorrhagic
intracranial tumors resulting in premature lethality.

8.

β8 silenced THA tumors displayed minimal invasiveness evidenced by in
vitro and in vivo studies.
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9.

Stark differences in tumor growth and angiogenesis in control versus
silenced THA tumors were, in part, due to impaired integrin-mediated
TGFβ activation.

Identifying αvβ8 integrin’s involvement in brain tumor-associated vessel
pathologies further establishes integrin biology as a key determinant in low- versus
high-grade human gliomas.

This knowledge could provide insights into the

development of more targeted therapies to reduce tumor severity, thus resulting in
increased patient survival.

Unfortunately, current treatment for GBM is highly

ineffective, only extending survival 5-10 months longer with an aggressive regime of
concomitant radio- and chemotherapies that compromises quality of life.

Anti-

vascular agents have begun to show promise in the clinic as bevacizumab as
recently been FDA-approved for the treatment of recurrent gliomas. Unfortunately,
these agents are not used during primary treatment of newly diagnosed patients
because of a poor benefit to risk ratio shortly after initial tumor resection. Therefore,
more targeted therapies are necessary in the clinic in order to improve dismal
median survival rates of GBM-diagnosed patients, which have not significantly
changed over the past several decades.
This is the first investigation of αvβ8 integrin in GBM; however, there are
many interesting future directions that should be pursued as a result of the data
presented. First, further inquiry into αvβ8 integrin’s involvement in human glioma
invasion should be studied as obvious differences were seen in the transformed
human astrocyte mouse model. Additionally, mice harboring control and integrin-
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silenced tumors should be sacrificed earlier, i.e. 14 days post-injection, to determine
whether the significant growth differences were a result of increased angiogenesis
or tumor cell proliferation.

Moreover, this same study should be performed

analyzing the αvLO and αvHI sub-population tumors. Lastly, additional exploration of
other mechanisms behind those pathologies presented should be further analyzed.
The integrin’s role in endothelial cell homeostasis was clear, although a more
detailed analysis should be researched in order to determine if the TGFβ
bioactivation has more consequences in a para- or autocrine manner.
Further analysis of intracellular signaling within the tumor cells could also
provide insights into the striking vascular pathological differences evidenced in this
investigation. There is limited intracellular knowledge about how genetic ablation or
stable silencing of β8 integrin in tumor cells affects tumorigenesis.

Perhaps,

dissecting the auto- and paracrine molecular pathways as a result of this loss may
further provide understanding in regard to αvβ8 integrin during gliomagenesis.
Additional co-culture assays involving tumor cells and endothelial cells, such as
tube formation or transwell assays, could reveal added mechanistic understanding
behind the pathologies observed.
In addition to the various mouse models presented, the RCAS-N-tva mouse
model could be valuable, commonly known for its initiation of ‘endogenous’ tumor
formation upon retroviral delivery of potent oncogenes.

Upon RCAS-PDGFβ

overexpression in the glial-specific N-tva model, low-grade III oligodendrogliomas
appear (154). It is possible an endogenous tumor microenvironment devoid of αvβ8
integrin expression could push the tumors pass the threshold, classifying them as
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grade IV GBMs.

Furthermore, additional potent RCAS vectors such as

myristoylated-Akt, K-Ras or VEGF concomitant with β8 integrin loss could increase
tumor severity as well. Other brain cancers could also be investigated, such as
pediatric brain tumors, e.g. medulloblastoma.
Taken together, this thesis has provided a potential therapeutic target to
further investigate based upon αvβ8 integrin’s involvement in glioma-induced
angiogenesis, which could contribute to possible increased prevention (lower grade
to high grade) and early diagnosis of GBM.
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